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An Analysis of The Use of Wearable Technology as A Means of Controlling 
Drug Delivery Systems And The Challenges Facing Its Usage In Ireland  
by Adewumi Bolatito Temitayo 
In this study, the possible/existing use (in Ireland) of wearables (such as the 
smartwatches, patches, and contact lenses) in controlling drug delivery systems (such as 
pumps and nanoparticles) was analysed. The challenges affecting the use of this 
technology in Ireland were determined. The public and potential customers' perception 
of the novel technology was examined along with how the creation will be potentially 
received in the market. Ireland was the country of choice because the researcher resides 
there and because of the heavy presence of many pharmaceutical companies in the 
country.  
The secondary research was conducted by looking into the concept of controlled drug 
delivery and how it works. The history, uses and the market for wearable devices was 
explored globally and in Ireland. The concept of wearable device-controlled drug delivery 
systems was then introduced. The different commercially available ones were analysed 
and the challenges facing the use were examined. The data collection involved 
quantitative research via questionnaire (219 participants) to establish the challenges 
facing the development and manufacture of this type of drug delivery system. The 
knowledge and views of Irish consumers concerning the use of this technology were 
established. Qualitative data was also collected via interviews (of 3 industry experts) to 
further explain these technologies and determine the level of progress in the research & 
development and manufacture of the devices in Ireland. 
The use of wearable devices in controlling drug delivery systems is still at its early stage 
in Ireland and some people have little or no knowledge of the use of this type of drug 
delivery system. Majority of the participants were interested in using the technology 
(83.5%), 65.6% would rather use this wearable device-controlled drug delivery system 
because more than half of the participants trust that this type of drug delivery system is 
more effective. Some of the limitations of the use of this type of drug delivery system 
from the consumers’ point of view are based on the concerns on the high cost, efficiency, 
and accuracy of this type of drug delivery system. The size, look, comfort, and ease of 
use of these devices influence the use of this type of drug delivery system. According to 
the industry experts, challenges like heavy regulations and the massive amount of time, 
money, and resources involved in the Research & Development affect the manufacture 
and use of wearable device-controlled drug delivery systems in Ireland. 
Keywords: Drug Delivery, Wearable Technology, Wearable Devices, Ireland, 
Drug Delivery Devices, Controlled Drug Delivery, Drug Delivery Systems, 
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CHAPTER 1: INTRODUCTION 
1.1. OVERVIEW 
This research is based on using wearable devices in controlled drug delivery and the 
challenges involved in the design, manufacturing, and sales of the devices. It is only 
focused on controlled drug delivery systems and does not include its use in other forms 
of drug delivery. 
This dissertation is also aimed at determining the challenges affecting the use of this 
technology by discussing with experts the pharmaceutical and medical devices industry, 
especially in Ireland because of the heavy presence of frontier pharmaceutical companies 
in Ireland. It will examine how the public and potential customers perceive such creation 
and how it will be potentially received in the market.  
1.1.1. INTRODUCTION TO WEARABLE TECHNOLOGY 
Wearable technology otherwise know has wearable devices can be described as an item 
that has electronics and computers incorporated into it (Wright and Keith, 2014). A 
wearable device is usually worn as an accessory that has an implant that has an interface 
to perform simple tasks but provides its initial aesthetics purpose (Wilson and Laing, 
2018). These devices carry out functions like our smartphones and laptops and more 
because they possess sensory and scanning characteristics such as biofeedback. They 
can be in the form of clothes, watches, headbands, jewelleries, etc, or in invasive forms 
like microchips and smart tattoos which can be implanted in the body and are used for 
different purposes across all aspects of life (Wright and Keith, 2014). 
Technology has been immensely used in the improvement of the quality of life and has 
transformed the healthcare sector. One of the technologies used in the improvement of 





With the continuous innovation in the technological industry, advancement has been seen 
in the measurement of physiological and biochemical activities in the body such as blood 
oxygen saturation and protein levels making it possible for them to be determined outside 
the hospital laboratory (Chiauzzi et al., 2015). 
The need to provide accessible and affordable healthcare has increased the demand for 
portable medical devices that can be used by both patients and professionals anywhere. 
To achieve this, a portable and effective monitoring system that be specific for individuals 
is needed. These portable devices are in the form of wearable devices that can collect, 
analyse, store, and disseminate data such as body vital signs. Technology has been able 
to provide information that can be used by health professionals to provide fast and 
effective treatment (Sungmee Park and Jayaraman, 2003). 
 Over the past few years, different technological developments have been made 
regarding the use of wearables such as smartwatches and fitness bands for several 
functions. These functions range from its use to pay for goods and services promoting 
the cashless policy e.g. FitPay to its use to monitor body vital signs such as sleeping 
patterns, heart rate, and the number of calories burned to mention a few. The functions 
on the wearable devices have made them useful in different fields like the education, 
entertainment, and healthcare sectors (Wright and Keith, 2014). For this research, the 
use of wearable devices in healthcare will be the focal point.  
Examples Wearable Devices includes:   
i. Wearable Motherboard™  
ii. Activity Trackers 
iii. Smart Watches 
iv. Smart Clothing 
v. Smart Patches 
vi. Ingestibles 




viii. Google Glass 
1.1.2. INTRODUCTION TO DRUG DELIVERY SYSTEMS 
The Mechanism of Drug Delivery can be described as all the different methods used to 
get therapeutic substances into a living organism to enhance drug therapy thereby 
boosting the overall clinical response of the organism  (Bruschi, 2015). 
Drug delivery systems are very important in the treatment of different types of diseases 
as it is responsible for the ensuring that the site in the body that needs the therapeutic 
substance get the substance in time and in the right concentration. Because of its 
importance, there has been constant research and development of novel and effective 
drug delivery methods (Nayak et al., 2018). These new developments in drug delivery 
systems also provide an alternative to the development of new drugs as new delivery 
methods can help in using the same therapeutic substance to treat different other 
diseases. This is a better alternative for pharmaceutical companies as the cost of 
developing new delivery methods is lower than the cost of developing a new drug 
substance (Tiwari et al., 2012). The importance of choosing and improving the right drug 
delivery system includes the following: 
a) Helps to enhance the patient and product safety 
b) Improves the convenience of the use of the drug.  
c) Controls drug exposure overtime (Bruschi, 2015). 
Some of the popular materials used in novel drug delivery systems include Liposomes, 
Proliposomes, Microspheres, Gels, Prodrugs, Cyclodextrins, Nanoparticles(Tiwari et al., 
2012). 
For this research, the controlled drug delivery system also known as the controlled-
release technology (CRT) will be focused on. CRTs are new drug delivery systems that 
include iontophoretic devices for administering drugs through the skin, some 




i.  Beaded delivery system 
ii. Transdermal and transmucosal controlled-release delivery systems,  
iii. Drug-impregnated lozenges 
iv. Encapsulated cells 
v. Oral soft gels (Tiwari et al., 2012) 
1.1.3. WHY IRELAND? 
Ireland can be considered home to many big and small pharmaceutical companies. These 
companies all fall between the 3 divisions of the pharmaceutical industry namely: 
- Biopharmaceuticals (Biotechnology) 
- Medical Devices and Diagnostics 
- Oral/ Solid Pharmaceutical companies 
The Pharmaceutical sector in Ireland can be dated to as far back as the 1960s and 
currently employs over 30,000 people and has contributed to about $10billion in capital 
investment in Ireland over the last 10 years. Ireland boasts of having about 75 
pharmaceutical companies which include 10 out of the top 10 pharmaceutical companies 
in the world (IDA Ireland, 2020). The pharmaceutical industry has carved a niche in the 
Irish economy to be a successful cornerstone. This sector has been a major source of 
employment creating splendid careers for Irish youths and attracting foreigners into the 
country. There are about 40 companies that have been approved by the FDA that are 

















Ireland is ranked 7th among the exporter of pharmaceutical products in the world bring 
about €39 billion export revenue to the country (IDA Ireland, 2020). 
 
Figure 3: Ireland's ranking in pharmaceutical production (Liorančaitė, 2015). 
1.2. AIMS AND OBJECTIVES OF DISSERTATION 
The research was embarked to identify the innovative ways to deliver drugs to target 
sites of actions with much less frequency in the administration of the medicine. New 
developments have resulted in the use of controlled drug delivery systems in modern 
drug delivery, for example, wireless Microelectromechanical systems (MEMS) are been 
used in drug delivery in the pharmaceutical industry. The use of wearable devices in 
healthcare has opened the way for their use in drug delivery. The use of wearable devices 
can be a form of solution to controlling drug administration and delivery systems. This 
research aims at exploring how wearables devices can be incorporated in the control of 




The objectives of this research are to:  
1. To define the process involved in the research, development, manufacture, and 
sale of the wearable device-controlled drug delivery system in Ireland. 
2. To identify the risks and challenges involved in the process in Ireland. 
3. To examine the effectiveness of this novel technology in Ireland. 
4. To define the potential market target and general view about the technology in 
Ireland. 
1.3. RESEARCH QUESTIONS 
In recent times, several technological advancements are constantly been achieved and 
one such is the evolution of wearable devices such as smartwatches and fitness bands to 
monitor body vital signs. This technology has been incorporated into the pharmaceutical 
industry by using it to control the drug delivery system through different means of 
controlled-release dosage forms. The wearable device can detect the shortage of the 
therapeutic substance and sends a signal to the drug delivery system to release the 
therapeutic substance in a controlled manner according to the predetermined dosage. 
However, the use of this technology in Ireland has not been well established despite the 
heavy presence of many pharmaceutical companies in the country. This dissertation 
examined the challenges affecting the use of this technology, especially in Ireland. It also 
looked at how the public and potential customers perceive such creation and how it will 
be potentially received in the market. 
For this reason, the research questions for this research are: 
1. How can wearable devices be used to control drug delivery systems?  
2. What type of industrial collaborations are involved in the creation of 





3. What are the challenges that can affect the use of wearable devices to 
control drug delivery in Ireland? 
4. Who is the potential target market for this wearable device-controlled 
drug delivery system in Ireland?  
5. How will this new technology be received in the market in Ireland? 
1.4. SIGNIFICANCE OF THE RESEARCH. 
The delivery of drugs using new technologies is a constantly changing area in drug 
development a part of pharmaceutical studies that the author has always found 
fascinating. In the same way, the use of wearables has exponentially increased over the 
past few years, this has prompted many studies about their use in healthcare. This 
research will help enlighten and enable further understanding of the different studies that 
have been done to find innovative ways to deliver drugs to target sites of actions with 
much less frequency in the administration of the medicine. 
This research will explore how patients can administer their drugs at home using simple 
procedures with help from their wearable devices. The wearable device can detect the 
shortage of the therapeutic substance and sends a signal to the drug delivery system to 
release the therapeutic substance in a controlled manner according to the predetermined 
dosage. This will help reduce the length patients will have to stay in the hospitals leading 
to a better overall healthcare system has more people will be able to access it. The use 
of wearable device-controlled drug delivery systems will improve the convenience of the 
use of the drug which will lead to better compliance which will result in better treatment 
outcomes. 
By defining and analysing potential market targets, pharmaceutical and medical devices 
companies will be able to better understand what their customers want. This will help in 
reducing the time spent on the research and development of the technology thereby 




Finally, although the use of wearable devices in healthcare has been extensively 
researched, its use is a means of controlling drug delivery systems is still at its early 
stage, this research will bring to light the benefits and challenges involved in using these 
devices for drug delivery. This research hopes to help hasten the use of technology in 
Ireland. 
1.5. ACCESS AND RESEARCH ETHICS ISSUES 
For this research, both primary and secondary data were collected. The secondary data 
was collected by going through the previous works done on the topic and finding out 
more about all the elements involved in this research. This information was accessed by 
looking through different journals, articles, thesis, and books. The primary data was 
collected by interviewing experts from both the pharmaceutical and medical device 
industry. Because of the COVID-19 pandemic, face to face interview could not be done, 
all the interview was done via Zoom. This affected getting non-verbal communication like 
body language, environment, tone of voice, and gestures could not be determined. Also, 
the initial plan of physically handing out and filling of questionnaires was moved to an 
online platform.    
During this research, all ethical guidelines were followed. All the data collected were 
treated with uttermost confidentiality and anonymity. Good behaviour and 
professionalism were displayed, and the people involved did so willingly. 
1.6. STRUCTURE OF THE RESEARCH 
The second chapter of this research will be the literature review focusing the controlled 
drug delivery and wearables. The history, uses and the global and Irish market for 
wearable devices (especially in healthcare) will also be explored. The concept of wearable 
device-controlled drug delivery systems, its different applications, and the different 
commercially available ones will be investigated. The challenges facing the design, 
manufacture, and use of this type of drug delivery system will be examined. This chapter 




The third chapter is focused on the method of data collection. For the primary research 
of this dissertation, the qualitative approach using interviews and questionnaires was 
used. The interview was focus on experts from both pharmaceutical and medical device 
industries exploring the experience and knowledge in the area and establishing the 
progress made in the research and development of the technology so far. Quantitative 
data (questionnaires) with 219 participants involving the general Irish population focusing 
on the views of people about the new technology and how well/ ready they are for it.   
The fourth chapter of this research consists of the analysis and findings from the data 







2. LITERATURE REVIEW 
The constant evolution of mobile and digital technology has transformed the world and 
the quest to have it further incorporated into more parts of our life has birthed wearable 
technology also known as wearable devices. Wearable technology can be defined as the 
presence of computers in clothes and/or clothing accessories and its origin can be dated 
to as far back as 1960. The use of wearable devices has been on the increase all around 
the world and Ireland is not left behind (Weng, 2016).   
In a publication titled “Wearable Technology: Present and Future”, the author gave a 
summary of the state of wearable technology. This research focused on the components 
of wearable devices, history, and the application of wearable devices. Data in the paper 
were collected by conducting a thorough literature review of 100 research papers, 10 
market reports, and 30 company websites. The author concluded that the major 
components/ elements needed in making a wearable device a wearable device include 
sensors, microchips, power sources, and software. Sensors are used to measure or detect 
biological and environmental variables such as temperature, heart rate, respiration rate, 
activity, or presence of a substance. It can also be used to produce signal or indication 
and to launch responses to a change in the level of a variable. Other components vary 
depending on the type of accessory the wearable device would be (Wilson and Laing, 
2018).  
2.1. MARKET FOR WEARABLE DEVICES 
In the publication “Wearable Technology: Present and Future”, the author also gave an 
insight into the progression of wearable technology and how it was adopted by the society 






TIMELINE WEARABLES  
16th 
century 
Introduction of wristwatch basically for women as men were still using 
pocket watches. Development continued even to the 20th century. 
17th 
Century 
Smart ring (abacus) 
1890 Hearing aids that progressed to digital hearing aids and now smart 
hearing aids in 2016. 
1960 The use of timing devices and hidden cameras for cheating in casinos. 
1965 Development of pedometers 
1970 Calculator watches 
1979 Walkman®  
1985 Electronic devices in clothes 
1996 Smart garment such as the Georgia Institute of Technology Wearable 
MotherboardTM which has been improved to birth other smart clothing 
2009 The launch of fitness bands/activity trackers as an improvement from 
pedometers 
2010 Smartwatches with the ability to text, call and access internet among 
other features 
2013 The beginning of smart spectacles: GoogleTM Project Glass 
2015 Introduction of smart patches for medical application 
2016 Smart sporting gears such as swimming tracker, golf band, and cycling 
band. 
Table 1: Timeline of developments of wearable devices (Wilson and Laing, 2018). 
North America and Europe are one of the leading markets for wearable devices, but Asia 
is projected to lead the market soon according to market projections. The market in North 
America is associated with its large population and disposable income while the market 
in Europe is associated with the awareness of the importance of the devices especially in 





Figure 4: Market Size by Products of US Wearable Technology 2016-2027 (USD Billion) (Grand 
View Research, 2020) 
The wearable technology market was in 2019 worth over $50 billion globally and the 
number of people using this technology (connected to a 4G network) was 526 million and 
this is expected to increase to 900 million by 2022 (Pindel, 2020). Smartwatches were 
recorded to be the most successful wearable device in 2017 (Wilson and Laing, 2018).  
According to a survey carried out in the United State for wearable fitness technology, it 
was concluded that the factors influencing the use of these devices are (Pindel, 2020): 
• Income- About 50% of high-income earners own one, 30% of middle-income 
earners use it and only 25% of low-income earners use one. 
• Location- People living in urban areas tend to use it more than those living in rural 
areas 
• Gender- More women use these devices more than men.  
• Age- People below 55 years were twice likely to use the device more than people 




In a report titled “Wearables 2019: Advanced Wearables Pick Up Pace as Fitness Trackers 
Slow”, the author looked at the consumer trends in the wearable market and presented 
a forecast on the use of wearable devices in America. In the report, the market for 
wearable devices were younger people (Wurmer, 2019).  
 
Figure 5: Wearable Users and Penetration among US Adults between 2017 and 2022 (in millions 
and % of population) (Wurmer, 2019). 
In 2015, 24% of people aged 25 to 34 had a wearable device, while 6.5% of those aged 
55 to 64 had one. A forecast of about 25% of American adults is estimated to use 
wearable devices in 2019 was given and the largest age group was still going to be the 
younger generation with about 38% owning one. The market penetration among older 





2.1.1. USE IN IRELAND 
In 2015, a nationwide survey was carried out in Ireland to understand the usage and 
impact of technology in Irish homes. The survey by eir telecommunication company, 
aimed at documenting the social changes experienced in Ireland because of technology 
and innovation including the rise in the use of digital devices. The survey used a 
quantitative approach and it included 1,013 Irish households. The participants were all 
aged above 16. The survey concluded that about 8% of the participating household had 
at least one wearable device in the household. Also, 20% of the adults were interested 
in getting one. People aged 16-24 years old were the most interested in getting a 
wearable device while people over 65 years were the least interested with only 4% 
interested. The other age brackets 25-34, 35-44, and 50-64 recorded the following 
percentages respectively 29%, 19%, and 10% showing a decline in interest in older 
people (eir, 2015). 
This survey shows the history of the use of wearable devices in Ireland and is very useful 
in determining the use of wearable device-controlled drug delivery systems in Ireland. 
2.2. COMMERCIALLY AVAILABLE WEARABLE DEVICES IN HEALTHCARE 
The use of wearable devices in healthcare can be dated as far back as 1996 when the 
Wearable Motherboard also refer to as the smart shirt was developed by Georgia Institute 
of Technology, sponsored by a U.S. Navy Defense Research Grant. This technology like 
many other technologies has evolved over the years from large-sized and uncomfortable 
devices to smaller, portable, sleek, and fashionable devices (Wright and Keith, 2014). 
Their use has been seen in areas such as diagnosing, treatment, and monitoring of 
patients. It also enables the transfer of medical care from hospitals to other external 
environments which in turn reduces hospital stays and allows for better healthcare 
systems in the society. It also facilitates constant care for the elderly and those living 
with chronic disease, therefore, reducing death rate and increase life expectancy (Wilson 




2.2.1. WEARABLE MOTHERBOARD™ 
This is a “Smart Shirt” that make use of sensors and other forms of monitoring devices 
to discreetly observe the overall wellbeing of people. It was originally designed to detect 
bullet wounds and monitor the vital signs during combat but was then converted for 
civilian use. The sensors are used to measure things like the heart rate, body 
temperature, pulse, etc, and can be positioned anywhere on the body. The information 
generated from the smart shirt is collected, processed, and transmitted to the desired 
location such as the hospital. Information can also be sent back to the smart shirt giving 
suitable directions for the situation. The shirt was built in a way that any sensor can be 
added to it depending on the use such as health and fitness and public safety (Sungmee 
Park and Jayaraman, 2003). 
  





2.2.2. ACTIVITY TRACKERS  
Activity trackers can be in different forms and can be used to measure different health 
activities like the mobility of patients. In an experiment carried out using Fitbit® wireless 
accelerometers to monitor the mobility of post-surgical patients, it was noticed that the 
data monitoring was easier. The activity tracker also made it possible for early discovery 
and treatment of post-surgical outcomes (Cook et al., 2013).  
 
Figure 7:Jawbone UP24 and its Apple app (Hussain, 2014). 
These devices are made available as bracelets, wrist bands and are usually synchronised 
with mobile phones and/or computers. some of the commercially available ones are 





2.2.3. SMART GLASSES (GOOGLE GLASS)  
Google Glass is a glass incorporated with processing units, flash memory, high-resolution 
display, and capable of taking pictures and videos. It is rechargeable, equipped with 
connectivity to both Wi-Fi and Bluetooth with a memory of about 12GB that can be 
synchronised with Google Cloud. This type of wearable device is being used by healthcare 
professionals for different activities such as streaming operations online, hold video 
consultations with colleagues during a difficult medical operation, view patient records/ 
test records without leaving the room or patient (Wright and Keith, 2014). 
 
Figure 8: A diagram outlining the components of Google Glass (Purcher, 2014) 
The Evena Medical’s Eyes-On Glasses helps in the placement of intravenous lies by 
showing the anatomical images to the health professionals which could in turn prevent 
mistakes and multiple needle punches. Also, smart glasses for partial and fully blind 
people are being developed by scientists at the University of Oxford. These glasses will 
make use of 3D cameras to notify the wearer about objects ahead. Another commercially 
available smart glasses are “the Vuzix glasses” which possess voice recognition, sensors, 






These are watches that have the same abilities as a smartphone including the ability to 
run mobile apps (Wright and Keith, 2014). Fitbit®, Amazfit®, and Apple Watch® are 
popular examples of smartwatches that are being used to monitor vital body signs like 
activity level, blood pressure, heartbeat, sleeping patterns, etc. it has been used in 
improving fitness and enhancing the monitor of health (Chiauzzi et al., 2015). 
 
 
Figure 9: An Apple Smartwatch showing some of its applications(Allison, 2017) 
2.2.5. SMART TEXTILES  
This is a type of clothing developed mainly for fitness users. In 2014, OMsignal, a 
company based in Montreal came up with a shirt containing sensors that can be used to 
check and monitor breathing and heart rates, calculate calories burned and determine 




power it (Wright and Keith, 2014). An example is the range of t-shirts, vests, and other 
sports clothing developed by a smart clothing company called AiQ. One of their products, 
Bioman+ is an upper-body garment made using “conductive fibre-based textile 
electrodes” that carry, process, and transmits electric signals. It is known for its use in 
monitoring heart rate and ECG (AiQ Smart Clothing, 2017). 
 
 
Figure 10: A Bioman+ female vest (AiQ Smart Clothing, 2017). 
2.2.6. FASHION ACCESSORIES  
There is a range of bracelets, bands, and necklaces that have information technology 
capacities. An example is a product called CuffLinc by Cuff (a wearable device company). 
CuffLinc is embedded into these accessories and is connected to the mobile phone via 




designated area on the accessory, the device sends a distress message and to an 
appointed person (as set by the wearer). It is primarily used for personal security and is 
very useful for elderly people living alone in crisis to reach loved ones. This device has 
improved from having a non-rechargeable battery that lasts for about a year to a device 
that can also check vitals and is chargeable (Wright and Keith, 2014). 
2.2.7. OTHERS 
Many other devices are being used in healthcare and many more a still being discovered 
and developed to improve the overall quality of health of patients. An example is a bionic 
glove that is being used to rehabilitate patients with spinal cord injuries and stroke by 
creating electrical stimulation to allow them to regain the use of their hands (Wilson and 
Laing, 2018). Other available devices are Patches and Tattoos, Ingestibles, and Smart 
Implants (Chiauzzi et al., 2015). 
2.3. CONTROLLED DELIVERY OF DRUGS 
For the drug delivery system to work, it makes use of one or more biological processes 
like diffusion, osmosis, and partitioning. Controlled drug delivery systems are usually 
classified based on the type of process used (Bruschi, 2015).  
2.3.1. OSMOSIS 
This very useful in rate-controlled drug release systems which can span from as short as 
24 hours to as long as several months or years. It can be used in combination with other 
systems. It is the movement of solvent through a semipermeable membrane diluting a 
solution to an equal concentration. The solvent in an organism is usually water that moves 
across the biological membrane and is an important process in living organisms. It is used 
by the drug release system to absorb water from the body into the osmotic material 
causing it to swell and leads to a slow release of the drug. This process is commonly 





This is a process that involves dissolving the API in a solvent leading to the ionization of 
the molecules of the API into the medium. The drug’s dissolution rate can be used to 
predict the release rate of the drug and used as a tool for the controlled drug delivery 
system. This is achieved by coating the drug substance with materials of varying thickness 
or by scattering them in a polymeric matrix (Gandhi, 2013). 
2.3.3. SWELLING 
This the reaction between water molecules and the molecule of a substance. The 
substance used for controlled drug delivery systems is usually polymers and when these 
polymers are surrounded by water, the components expand creating chemical/physical 
bonds. This expansion is used to control the drug release from its polymeric component. 
Hydrophobic polymers don’t usually swell substantially, it’s swelling velocity can be used 
to control the release of the drug (Ranga Rao and Padmalatha Devi, 1988). It makes use 
of hydrogels which when taken orally incorporates other processes such as drug 
dissolution, water diffusion, and polymer chain relaxation to release the drug substance 
(Caccavo et al., 2016). 
2.3.4. PARTITIONING 
This involves the use of affinity and polarity of molecules to move them from one phase 
to another. This is important especially for APIs that have to move between aqueous and 
lipid bio phases. This property can be used to design micelles drugs with hydrophobic 
cores and hydrophilic coronas controlling the time for each release of the API (Bruschi, 
2015). 
2.3.5. DIFFUSION 
This is the movement of molecules from one end of a system to the other in random 
motions using the concentration gradient reducing the difference in concentration in the 
system. Diffusion is essential to get APIs across cell membranes and for it to be 




It is more effective in short distances losing its efficiency over long distances (Gandhi, 
2013). 
2.3.6. EROSION 
Some polymers undergo erosion when they go through chemical reactions such as the 
hydrolysis of bonds, releasing the API embedded in them. The erosion of these 
biodegradable membranes controls the rate of drug release. If the rate of erosion is high, 
the quantity of API released maybe too much and if the rate is low then the possibility of 
elimination of the whole system from the organism without the release of the API is 
possible (Kamaly et al., 2016). 
2.3.7. TARGETING 
This the ability of an API to gather all or most of its concentration at the site of action 
only no matter the site or the route of administration. It can be done at organ, tissue, 
cellular, or organelle levels. Targeted drug delivery can be described as the accumulation 
of APIs in the site of action by retaining, evading, targeting, and releasing (Bruschi, 2015). 
2.4. WHY WEARABLE DEVICE-CONTROLLED DRUG DELIVERY SYSTEM 
2.4.1. EASE OF USE 
No matter how good or effective a delivery system is, the device should be relatively easy 
to use such that anyone can use it effectively. It should be that a patient or caregiver 
should be able to use the devices with little or no help from physicians. The ease of use 
goes a long way in determining the consistency of use by the patient as it influences the 
patient’s behaviour and interest to use. It is also expected that the device should be 
capable of providing a prolonged dose of the drug substance so that the rate at which it 
will be changed is reduced (Siew, 2018).  
2.4.2. BETTER TREATMENT OUTCOME 
If this technology is used correctly, it increases the number of patients that will adhere 
to the prescribed regimen which in turn will boost the success rate of the treatment which 




companies as it will increase the market for the product which is needed in the highly 
competitive pharmaceutical industry and also increases the asset value of the company 
(Huddleston et al., 2019).  
2.4.3. COMFORT 
One of the aims of wearable device-controlled drug delivery systems is to reduce the pain 
and discomfort that comes with conventional drug delivery methods like injections and 
drips. It aims at reducing the discomfort such that self-administration can be achieved 
with maximum compliance to the use of the drug substance. For example, wearable 
injectors help reduce the discomfort by decreasing the flow rate of the drug substance 
as pain increases with the flow rate (Siew, 2018).  
2.4.4. ECONOMICAL 
In the US, the cost of healthcare increases yearly by about 4%. This could be avoided if 
more therapies are done from home. Using this technology enables self-administration 
which reduces the time for in-clinic visitation. It also decreases the travelling expenses, 
administration costs, disruption of the lifestyle of the patient (Huddleston et al., 2019).   
2.4.5. INTERNET OF THINGS (IoT)  
This technological progression has allowed the interconnectivity of many devices and 
daily activities to make life easier (Dunkley, 2020). Moving the delivery of drugs into this 
circle will help solve problems of non-compliance of patients (Chourasia and Jain, 2003).  
2.4.1. INCREASE IN RESEARCH AND DEVELOPMENT 
The constant technological advancements in pharmaceuticals are very important to 
improve the way the diseases are been treated in these new times (Huddleston et al., 
2019). This constant research and use of these new technologies help birth other 
technologies which would be very useful in combatting many of the problems that still 




bioavailability, drugs that in the past required large doses before plasma concentration 
could be achieved now require smaller (Huddleston et al., 2019).   
 
2.5. EXAMPLES OF WEARABLE DEVICE-CONTROLLED DRUG DELIVERY 
SYSTEMS 
2.5.1. WEARABLE INJECTORS 
Most of the drugs in recent times are biologics and are becoming more focused on 
personalized medicine. Although they have excellent safety and efficacy profiles, it is quite 
difficult to administer to patients and is usually taken in the form of intravenous injections 
(Siew, 2018). The delivery system helps move the API across physiological barriers, 
protects it from untimely excretion, and delivers it to the active site (Bruschi, 2015).  
Also, self-administration has become a popular trend among patients in recent times 
leading to a search for novel delivery systems by the pharmaceutical companies. Delivery 
systems such as autoinjectors and prefilled syringes are aimed at improving the ease of 
usage and ensure it meets all the required regulations (Siew, 2018). Challenges such as 
the large volume and dosage repetition affect the use of prefilled syringes and 
autoinjectors leading to a demand for a better delivery system that is safe and 
accommodates high volume drugs. This led to the innovation of wearable injectors which 
are stress-free, comfortable, and convenient. A wearable system can be used for a large 
volume of drugs and will be delivered at the right dosages over some time. The wearable 
device can be time-controlled and delivers drugs automatically at the set interval. This 
can also be removed when the dosage is completed (Siew, 2018). 
An example of a wearable injector is a device called enFuse developed by Enable 
Injections. It is a small single-use wearable device that delivers up to 50ml of high 
viscosity drugs subcutaneously. The container holding the drug and the delivery system 
are contained in a small device that is comfortable to wear and is discretely hidden by 




delivers the mixture using a very small needle that will not be visible to the patient which 
therefore reduces the anxiety associated with needle picking (Siew, 2018).  
 
Figure 11: A Wearable Injector showing its size (Huddleston et al., 2019). 
The device has variations that allow it to be used for multiple drug substances and be 
used to deliver varying doses specific to each patient.  The device also possesses 
connectivity to mobile apps to more and control compliance (Siew, 2018). 
The device makes use of a sequential elastomeric toroid pump and therefore, does not 
need batteries to function. This attribute enables the device to maintain a small size and 




Another commercially available example is a device called SmartDose developed by West 
which is a delivery device that is worn on the stomach of the patient that provides a 
hands-free administration (Siew, 2018). 
2.5.2. ORAL AND PARENTERAL DELIVERY SYSTEM 
This makes use of biodegradable polymeric devices to control the release of drug 
substances. It has been used for protein/peptide drug substances using intestine selective 
microspheres.  This system does not disintegrate in the stomach but in the intestine allow 
the drug to stay up to 6 times longer in the body. The biodegradable polymers are usually 
chosen based on their mechanical strength, biocompatibility, and biodegradability and 
some of the polymers used are poly (lactide-co-glycolide) (PLGA), poly (glycolide) (PGA) 
and poly (lactide) (PLA). A single dose of the drug in these polymers can last for days 
(Tiwari et al., 2012). 
An example of this delivery system is a project called IntelliDrug which involves 
developing a smart drug system implanted in the oral cavity. It was used to control the 
delivery of drug substances that get repressed because of the actions of the 
gastrointestinal/hepatic activities leading to low availability in the plasma. The model drug 
used in the project is called Naltrexone, a drug used in treating addiction alcohol and 
opioids, it is also to be used in the treatment of chronic diseases. In vivo testing 
established about 64% bioavailability of the drug in circulation and up to 10 times higher 
plasma levels. This is because the delivery system supplies the drug substance directly to 
fatty tissues or directly to blood circulation or the central nervous system. Increased 
bioavailability and the automation of the drug administration would increase patient’s 
compliance to the drug. This drug delivery system is small enough to be incorporated into 
a synthetic denture. It is also strong enough to withstand the force from chewing and 
the unconducive nature of the mouth. It contains a drug reservoir made of stainless steel 
and has an osmotic pump that could be filled and refilled with drug pills. The drug is to 




to be released it also has a fill-level sensor that determines when the reservoir is empty. 
(Goettsche, 2016).  
 
Figure 12: Prototype and Operation Principle Of The Intraoral Drug Delivery System Intellidrug 
(Herrlich et al., 2012). 
The sensors and controls send signals and are monitored using a wireless IR-
communication through the cheeks. The release of the is based on the pressure difference 




up allowing a flow of the drug at about 1.8 ml/h after which the valve is shut close 
(Goettsche, 2016). 
 
2.5.3. TARGETED DRUG DELIVERY SYSTEM 
Molecular targeting is also a type of drug delivery system that is been extensively 
researched as it is capable of tumour recognition through ligand facilitated interactions. 
This is made possible by the conjugation of liposomes with ligands such as fragments of 
antibodies, hormones, and vitamins. Studies have shown that this type of interaction is 
possible, and they provide effective delivery of encapsulated drug substances between 
cells. It has been targeted towards different organs such as lungs for the treatment of 
different respiratory diseases by reducing the side effect of the drugs, brain for 
addressing the issue of the blood-brain barrier where the water-soluble parts of the drug 
affect the necessary conversion (into lipid-soluble) needed to overcome the blood-brain 
barrier, skin for a controlled but faster delivery of drug across the skin and the colon to 
bypass the gastric pH and effective for the treatment of colonic diseases like Ulcerative 





Figure 13: Outline of a program for developing blood-brain drug targeting strategies derived 
from either chemistry-based or biology-based disciplines (Tiwari et al., 2012). 
Some drugs like Ventavis (used in the treatment of Pulmonary Arterial Hypertension) 
have short half-life which means they need to be used frequently – up to 9 times a day. 
But this form of controlled drug delivery system help provides prolonged drug release 
and improved biological distribution of the drug substance leading to a longer half-life 
and ensures convenience and compliance of the patient. Also, polymer-based drug 
delivery systems have helped in enhancing the direct delivery of drugs to the brain. 
Targeted delivery systems have led to the discovery of devices such as Metered Dose 
Inhaler which has revolutionized the treatment of lung diseases; Plastic reservoir 
connected to the blood vessels in the brain through an outlet catheter; Nanoparticles 
which have been used successfully in gene therapy, radiotherapy, antibiotics, etc to pass 
the blood-brain barrier; the Liposomal reservoir system is used in the controlled 




pressure-controlled colon delivery capsules (PCDCs) are some systems used for treating 
colonic diseases (Chourasia and Jain, 2003). 
2.5.4. IMPLANTABLE SYSTEMS 
This system is usually used for a controlled but continuous application of a therapeutic 
substance over many years (long-term therapy). It is an automated system and does not 
have any form of attachment on the patient’s skin and therefore does not require regular 
maintenance but rather the catheters are implanted in the desired site of target e.g. an 
insulin pump will be put in the adipose tissue. The drug is continuously delivered in small 
quantities but the quantity (i.e. plasma concentration) could be adjusted depending on 
the need of the patient (Goettsche, 2016).  
 
Figure 14: Setup of the controllable, implantable pump SynchroMed EL by Medtronic [D-MED1-
09] (Goettsche, 2016). 
The reservoir with varying volumes and is made from titanium is located in the middle of 
the system.  The reservoir is placed in a pressure chamber containing a pressurized 
medium and the release of the drug is controlled by the pressure of the pressurized 
medium on the reservoir. The presence of flow resistors helps to control the drug flow 




example of this system is the SynchroMed series manufactured by Medtronic. This model 
contains a syringe that is used to refill the drug reservoir and a bioretention filter is used 
to prevent bacterial invasion into the drug. The battery of the system can last for up to 7 
years which is how long it could take before there is a need to refill the system (Goettsche, 
2016). 
2.5.5. EXTRACORPORAL SYSTEM (WEARABLE INFUSION PUMPS) 
This type of drug delivery system is done without surgery. They provide solutions for the 
continuous delivering infusible drugs over a long period e.g. insulin. They also provide 
information about optimal drug concentration and dosing parameters for implantable 
pumps before the surgery is carried out (Goettsche, 2016).  
 
Figure 15: Schematic illustration of the extracorporeal insulin pump D-Tron-plus by Roche 
(Goettsche, 2016). 
An example is an insulin pump called the D-Tron-plus by Roche. It has a programmable 




the prefilled drug reservoirs. The dispensation of the drug is usually based on the rotating 
motion of the motor which is effective in control medical safety (Goettsche, 2016). 
2.5.6. OSMOTIC SYSTEMS (OSMOTIC DRUG DELIVERY PUMPS) 
This type of drug delivery system has been around for over 70 years. An example of a 
commercially available one is the Rose-Nelson pump [D-MAT-99], a single-use drug 
delivery system developed in 1955. It consists of 3 different compartments: 
- a solute (e.g. water) section of adjustable volume 
- an osmotic section, filled with an osmotic agent (e.g. solute of NaCl) 
- a drug section, filled with a solute of the drug 
 
Figure 16: Working principle of the Rose-Nelson pump (Goettsche, 2016) 
The solute section and the osmotic section are separated by a stiff semipermeable 
membrane which allows a volumetric rise in the osmotic section because the osmotic flow 
of water moves through the semipermeable membrane. This volumetric increase causes 
a deformation of the flexible nonpermeable membrane that separates the drug section 




substance. Different modifications that involve the complete replacement of the water 
and osmotic sections with in-vivo environmental conditions and a shell around the drug 
substance has been seen.   
Other examples of this system are ALZET® pumps by ALZA, the VITS system (Veterinary 
Implant System) designed for companion animals, and the DUROS® system (Goettsche, 
2016). 
 
Figure 17: ALZET® pumps by ALZA (DURECT Corporation, 2020). 
2.5.7. LIPOSOMAL DRUG DELIVERY SYSTEM 
This drug delivery system makes use of liposomes and other circulating macromolecules 
that have high permeability and retention. They are popular for reducing toxicity and 
enhancing the efficacy of anti-cancer agents because of their extravasating ability from 
tumour vessels. For example, anthracyclines are a group of highly efficient anticancer 
agents but its efficacy has been limited because it was found to lead to irreversible heart 




and elongated blood circulation at a largely reduced cardiotoxicity as a result of drug 
encapsulation. It has also been used in the treatment of infectious diseases. 
Liposomal drug delivery systems are also been used in physiological and passive targeting 
of tumour tissues but unfortunately not tumour cells. This is because the delivery system 
in the bead of protecting the liposome prevents the interaction with some metabolites 
including the tumour cells. Instead after extravasation, the liposome undergoes 
enzymatic degradation which is how the drug is released (Tiwari et al., 2012). 
2.5.8. BEADED DELIVERY SYSTEM  
This is used mainly for medications that require once a day intake. This system has been 
tested on tolterodine tartrate and is available as DETROL LA, a medication used to treat 
an overactive bladder by relaxing the muscle leading to control over the frequency of 
bathroom visits. The mechanism involves small beads carrying the active drug substance. 
The beads are made from inert substances and are enclosed in a delivery capsule. The 
release of the drug is controlled based on the acidity of the stomach (Tiwari et al., 2012). 
There are plenty of other different types of new technologies in drug delivery systems 
that are too many to mention. The method of drug delivery may be controlled or pulsatile 
release patterns which could be based on different mechanisms of action such as 
enzymatic, pH, temperature, electric, or polymer-chemical activation.  
2.6. CHALLENGES FACING THE USAGE OF THESE DEVICES 
2.6.1. SIZE 
When dealing with a wearable device-controlled drug delivery system, the size is 
essential. It determines the volume of the drug substance that will be contained in the 
device. If the volume is too small, it could lead to regular visits to the physicians to replace 
the finished drug substance which will end up defeating the purpose for the device. If the 
volume is also too big, the size could lead to the discomfort of the patient which could 
reduce the compliance to the use of the device (Siew, 2018). Also, the beauty and 




device is. A small sized device ensured optimum energy consumption which determines 
the battery life and subsequently the size of the battery to be used. Getting the devices 
to a miniature size sometimes proves difficult as many of the drug delivery systems have 
a lot of very important components (Goettsche, 2016). 
2.6.2. STABILITY 
The most important element of any drug delivery system is the maintenance of the 
integrity of the drug substance (Huddleston et al., 2019). The stability of the drug 
substance is very vital therefore suitable primary containers should be used for holding 
the drug substance. This is because there is a possibility of a reaction between the 
container and the drug which could either affect the concentration, quality, or efficacy of 
the drug substance and/ or destroy the holding container (Siew, 2018). Sometimes the 
stability of the delivery device in the long term is quite questionable. An in-depth analysis 
and research need to be carried out before the different components of the devices are 
used to avoid harm to the user (Goettsche, 2016). The device needs to be stable to 
prevent sterility issues which could be fatal for patients. Also, packaging and transport 
challenges could occur as a result of unstable products (Huddleston et al., 2019). 
2.6.3. COMPLEXITY 
The formulation of many drug delivery systems is complex. For example, in a lung-
targeted drug delivery system, creating and putting the substance in aerosolized form is 
quite difficult. Also, nanoparticles that are used in drug loading, target, release, transport, 
etc are quite unstable and exhibit cytotoxicity (Tiwari et al., 2012). The device to be used 
by the patient should be extremely easy to use to ensure compliance with the drug and 
not affect the day to day activity of the patient (Goettsche, 2016). If the device is not 
easy to use it can also lead to human errors which could disastrous and also discourage 






The delivery device must be accurate in delivering the prescribed dose drug substances 
because if the drug substance is too little it may not elicit the desired therapeutic response 
and if the drug is too much it could be harmful/fatal to the patient. Getting the device to 
deliver the exact amount of drug substance needed without error is very tricky as the 
device must be equipped to account for every drop of the drug substance. Also, the 
device is required to deliver the drug in the right anatomical space (Huddleston et al., 
2019).    
2.6.5. THERAPEUTIC EFFECT 
One of the challenges poised in using novel drug delivery systems is ensuring the 
efficiency of the drug substance. The success of the device depends on the bioavailability 
of the drug in the body and this is measured through plasma concentration. If the 
concentration of the drug substance is not within the therapeutic window, it will result to 
a poor drug efficiency. Also, if the bioavailability of the drug is too high then it can lead 
to an overdose of the drug (Goettsche, 2016).  
2.6.6. DATA ACCURACY SECURITY AND PRIVACY 
There are concerns about patient’s data integrity and security (how it would be protected)  
(Wright and Keith, 2014). There are also concerns that some of the data collected could 
be inaccurate leading to misguided treatment. Also, there is a potential problem with the 
logging of the measured data (Weng, 2016). Before the device can be used, everything 
that has to do with data integrity needs to be tested. The ability of the device to produce 
and reproduce data that are accurate, valid, and reliable is one of the things that are 
collected and compared to conventional methods of drug delivery during clinical trials. 
The data generated needs to be protected from hacking and software malfunctions to 




2.6.7. MARKET PENETRATION 
Consumer acceptance is crucial to penetrate any market, this can be hindered by little or 
no understanding of the function and capability of the product. Attention should also be 
paid to the users’ requirements as this is what ultimately influences the decision to buy. 
The consumers need adequate awareness because nobody will buy what they don’t know 
about (Wilson and Laing, 2018). Researches carried out in China in 2014 has shown that 
40.5% of the respondents felt that the use of wearable devices in healthcare is not yet 
fully developed to the point of usage (Weng, 2016).  
2.6.8. SAFETY  
The drug delivery devices to be used should be simple to understand and safe for the 
users, i.e. the health professional that will activate the device and the patient on which 
the devices would be used. Developing a system/device that will not cause any type of 
pain to the patient requires sophisticated technologies like micro-needling  (Goettsche, 
2016). If the product is not perceived as safe and reliable by the patients, it can reduce 
the purchasing decision of the consumer (Wilson and Laing, 2018). 
2.6.9. SUSTAINABLE POWER 
Many of this type of drug delivery system uses high voltage power therefore finding the 
right energy source for the device is very important and can serve as a threat to the 
marketability of the devices (Dunkley, 2020). Most wearables are electronic devices that 
need a source of energy such as batteries. These sources of energy need to be recharged, 
replaced, or refilled. The frequency of the need to replace the energy source is also one 
of the challenges involved in the design of drug delivery systems (Goettsche, 2016). 
2.6.10. CONNECTIVITY 
Connecting the wearable device to external devices such as apps on other wearables e.g. 
smartphones are one of the issues that needs to be overcome to ensure seamless use of 




drug delivery, monitor the administration of the drug substance, and also provide 
assistance when using the drug delivery system (Huddleston et al., 2019). 
2.6.11. COST  
This is one of the reasons for the reluctance of consumers using the devices (Dunkley, 
2020). Pharmaceutical companies have the challenge of reducing the cost of development 
and manufacture. They also have to maximise the speed at which the devices get to the 
market so that they will be able to make development and manufacturing costs plus profit 
(Huddleston et al., 2019). These types of drug delivery systems are relatively very 
expensive to make and to own (Wright and Keith, 2014).  
2.6.12. CONSISTENCY OF USE  
Another problem is to tackle the issue of ensuring constant usage of the wearable device 
as the studies show that about 45.7% of users abandon the wearable e.g. Smartwatch 
within the first month of use (Weng, 2016). 
2.7. WHAT INDUSTRIES ARE INVOLVED IN MAKING THESE DEVICES 
Intel, an electronic company specializes in microchips worked along with AIQ a 
company that develops electronic-based clothing (AiQ Smart Clothing, 2017). Their 
collaboration helped develop a t-shirt that makes use of conductive fibre to track heart 
rates which can be sent to a smartphone. The electronic part of the cloth is in a 
detachable small side pouch (for easy removal during washing). This shirt is estimated 
by the manufacturer to be used in constant monitoring of people with health conditions, 
the elderly, and children (Wright and Keith, 2014). 
The creation of a wearable device-controlled drug delivery system also involves the 
careful selection and partnership between companies that provide the high-quality 
container systems such as vials or cartridges needed to hold the drug substance and 












• The use can be dated back to 19th Century. 
• Being used in different sectors especially 
healthcare 
• Examples includes Activity Trackers, Smart 
Watches, Google Glass, etc. 
• Used by many people in the world and Ireland but 
most common in people below the 55 years. 
Controlled Drug Delivery 
• Uses pharmacokinetics and pharmacodynamics to 
control the rate at which drug substance is delivered 
to the body. 
• More effective than conventional methods 
• Cuts across different routes of administration.  
• Examples include Nanoparticles, Liposomes, 
Millispheres, etc 
Literature Gaps 
• Industries involved in the development and manufacturing of the wearable device-controlled drug delivery 
system in Ireland. 
• Process involved in the development and manufacture of the wearable device-controlled drug delivery system 
in Ireland. 
• Risks and challenges involved in the process in Ireland. 
• Effectiveness of this novel technology in Ireland. 
• Potential market target and general views about the technology in Ireland. 
The Use of Wearable Technology as A Means of Controlling Drug Delivery Systems 
• Enables patients’ compliance to treatment because it is easy, comfortable, and convenient.   
• Wearable device-controlled drug delivery systems are commercially available. 









From the different works of literature read, wearable devices have been seen to take the 
world by storm especially in the 21st century although its history dates to the 16th century. 
Its use in different sectors can be considered as one of the reasons for its exponential 
growth. Initially, the use of wearable devices among the older generation was low, recent 
times has seen a turnaround. This can be associated with the use of wearable devices in 
healthcare monitoring where body vitals are constantly being measured. The constant 
measurement of these body vitals has been helpful in the early detection of disease and 
quick treatment which helps contribute to the quality of life and increase overall life 
expectancy.  
Controlled drug delivery is the way to modern drug delivery methods because it has been 
shown to solve many of the problems affecting the conventional methods of drug delivery. 
The conventional methods are usually uncomfortable and unreliable has the body tends 
to inhibit the performance. For example, conventional tablets taken orally have the 
probability of been degraded in the digestive tracts by some gastrointestinal juice and 
therefore the drug loses its efficacy. Controlled drug delivery systems make use of 
pharmacokinetics and pharmacodynamics which helps control the rate at which drug 
substance is delivered to the target site leading to increased plasma concentration. This 
enables the drug substance to be more effective and therefore reduces the quantity of 
the therapeutic substance to be consumed by the patients. Controlled drug delivery is not 
limited and is being used across various routes of drug administration. 
Recent technological advancement has allowed for a further upgrade to controlled drug 
delivery systems. This involves using some wearable devices both internal and external 
and infusing them with Active Pharmaceutical Ingredient (API) so that they help release 
this therapeutic substance in a controlled manner and over a period in the predetermined 
quantity. Others make use of various connectivity methods such as Wi-Fi and Bluetooth 
to signals to and from the drug delivery system enabling it to monitor and detect a low 




to the target site. It can also alert the user when the delivery system is empty or low in 
power. There are many benefits to the use of wearable device-controlled drug delivery 
systems such as comfort, ease of use, safety, and effectiveness. Only a few of this type 
of drug delivery system are commercially available now due to the different challenges 
facing its manufacture and use such as cost, data integrity and safety, size, and lack of 
awareness among consumers. 
Also, there is a lot of information on the different types of new drug delivery be discovered 
constantly there is no data on the use of all these technologies among the Irish 
population. There is also no literature on the consumers/ patients’ perception on the use 
of wearable devices in the control of drug delivery in Ireland. To effectively analysis the 
use of this device in Ireland, the primary research will focus on defining the process and 
the risk involved in the development and manufacture of this type of drug delivery system, 
determine the effectiveness of the technology and analyse the view of the Irish population 









Strategy  Survey 
Methods  Questionnaire distributed 
online  
Interviews via Zoom 
Structure 5 sections with 26 
questions 
10 – 30 minutes of conversations 
Response Rate  73% (Sent 300 
questionnaire got 219 
respondents)  
50% (Sent messages to 6 people 
and got response from 3 people) 
Participants  219 People Who are 
Currently Living in Ireland 
3 People Who Are Vast in 
Knowledge of The Technology 
Table 2: An Overview of the Research Methodology 
3.2. RESEARCH PHILOSOPHY 
The philosophy for this research was Pragmatism as the research was based on the 
insight on social and experiential levels since the research was aimed to explore people’s 
points of view, from a different perspective across the industry and different people in 
the society. 
The questionnaires provided quantifiable data which was analysed and used in reaching 
various conclusions for the research. The interviews provided qualitative data by 
providing information that reflects the processes and effectiveness of the topic. 
During the research, the author ensured that there was no bias or interference of personal 
interest in the study, and only the data collected were used. This was promoted by using 
an online questionnaire which limited the interaction with the participant of the surveys 





Interviews were conducted to collect qualitative data which was focused on the honest 
opinions of the people with experience and knowledge of drug delivery systems to 
understand the effectiveness and level of the implementation of this technology in 
Ireland. The interview questions were asked in such a way that it was free from any form 
of bias from the author. 
3.3. RESEARCH APPROACH 
To determine the process and risks involved in the research, development, manufacture, 
and sale of the wearable device-controlled drug delivery system, the author applied the 
qualitative research method by carrying out interviews. The author also used a 
quantitative research method to define the potential market target and general views 
about the technology by questionnaire surveys. Therefore, the approach for the research 
was the inductive approach and the type of data collected was both qualitative and 
quantitative.  
The survey was distributed electronically to different people all over Ireland and they 
were requested to fill the questionnaire. The questions in the questionnaire were to 
decode the general perceptions of consumers/patients towards the use of wearable 
devices for the control of drug delivery systems. This allowed the author to identify how 
the wearable device-controlled drug systems are perceived leading to a recommendation 
that can be used by manufacturers has a starting for market survey. 
Although the process involved in the research, development, manufacture, and sale of 
the wearable device-controlled drug delivery system had been established by some 
literature read by the author, interviews were carried out to better understand how the 
whole process works. The interview was also conducted to get the opinion of the industry 
experts on the effectiveness of the technology. 
 The data collected from the primary research was analysed and compared with the 




3.4. RESEARCH STRATEGY 
The overall strategy for the research was to identify the level of the implementation of 
wearable technologies in the control of the drug delivery system and to establish the 
readiness and willingness of the use of this technology in Ireland. According to the 
literature review, no research has been made on the consumer perception of the Irish 
society on the use of this technology, neither is there a research on the challenges 
affecting the implementation of the technology in Ireland. The researcher, therefore, 
chose to use surveys in the form of interviews and questionnaires to get the data needed. 
Everyone who got the questionnaire was given a simple yet brief introduction to the 
research and that the research was in the fulfilment of a master’s degree in 
Pharmaceutical Business and Technology at Griffith College Dublin. The dynamics of the 
questionnaire was in such a way that is was easy to understand and follow with technical 
words and phrases explained. 
The questionnaire had 5 sections with 26 structured questions aimed at determining the 
general perceptions in the form of the willingness of consumers/patients to use wearable 
devices for the control of drug delivery systems. The questionnaire was dispatched 
electronically through Google Forms and the link was sent to different people. The 
questionnaires were filled without any input from the author to abolish any form of bias. 
The 1st section of the questionnaire was a letter to the respondent giving all the basic 
information. The letter was to gain an informed consent and to assure the participants 
that their data will be stored in line with the General Data Protection Regulation (GDPR). 
To further participate in the survey, the participant had to answer the question ensuring 
that they agree to informed consent. 
3.5. DATA COLLECTION METHOD 
All the questions in the questionnaire were directed at getting the opinion of consumers 




The 2nd section of the questionnaire was focused on getting General Data of the 
participants. The five questions in this section were aimed at classifying the participants 
based on gender, age, educational background, income, and field of work.  
The 3rd section was on the Introduction to Wearable Devices and it was made up of eight 
questions that established the relationship between the participant and technology. The 
questions were targeted to determine the frequency of use and what influences the use 
of these wearable devices.   
The 4th section which was titled Introduction to Drug Delivery System was aimed at 
determining the knowledge and relationship of the participants with drug delivery 
systems. The section contains five questions that examine the type of conventional drug 
intake method the participants are familiar with and how well they adhere to taking the 
drugs. 
The 5th and final section ties the wearable devices to controlled drug delivery and is made 
up of eight questions. The questions in this section were aimed at determining the 
popularity of these novel technologies among the Irish residents and to ascertain the 
opinion of the participants regarding the use of these wearable technologies. The section 
was also aimed at getting what influences the participants to use or not to use the 
technology including their concerns about the technology. 
The final question in the questionnaire was poised to get people that had experiences in 
these types of technologies and would like to be interviewed. 
The second part of the primary data collection which was the interview involved the 
selection of the experts will be based on their knowledge, skills, or influence in the 
manufacturing of such technologies. The open-ended interview involved 3 people with 
experience and knowledge of the manufacture and use of wearable device-controlled 
drug delivery systems.  




How can wearable devices be used to control drug delivery systems?  
The interview was aimed at getting experts' opinions on the manufacture and usage of 
these technologies, the companies involved, and what type of challenges that may be 
faced during and after development. It was also used to determine the readiness of the 
Irish society in using this type of technology  
The open-ended questions enabled the interviewees to express openly their views and 
perceptions. The interview was conducted via Zoom. 
3.6. SOURCES  
The questionnaire generated by the author was distributed among different people living 
in Dublin via the internet. Google Form was used to make the form that contained all the 
questions to be asked and a link was generated. It was this link that was sent to people 
online. The participants were obtained via LinkedIn and the author’s contacts. Also, all 
participants were asked to share the form with their contacts in Ireland too. The total 
number of participants was 219 involving different people of varying ages and 
occupations. The author then made use of Microsoft Excel sheet to evaluate the data 
obtained and they were collated in pictorial statistical charts such as pie and bar charts.  
For the interviews, positive responses from the final question in the questionnaire, and 
about 20 responses showed interest to be interviewed. The author went on to contact 
the 20 responses to ascertain their level of understanding and expertise on the research 
questions and 14 of the participant were dismissed because they didn’t have enough 
experience needed for them to answer the interview questions. Out of the 6 participants 
deemed qualified for the interview, 3 did not reply to the follow-up emails sent to fix the 
dates for the interview. In the end, only 3 experts were interviewed. 
For the secondary data collection, the researcher analysed the different types of drug 
delivery systems, how they are controlled, different wearable technologies, how wearable 




affecting its usage. The data was collected from academic literature and industry-related, 
publicly available documentation.  
3.7. ACCESS AND ETHICAL ISSUES 
Before taking part in the research via questionnaires or interviews, all the participants 
were provided with a brief introduction to the research explaining what the research is 
about and that the research was in fulfilment of her master’s degree. The data were 
collected in such a way that maintained the participant’s anonymity and all the questions 
asked were relevant to the research and aimed to attain the objectives set out to be 
achieved. Participation in the research was completely voluntary and the participants 
were informed of the right to withdraw from participating at any time.  
The data generated from the questionnaires and interviews were treated confidentially. 
During the interviews, the researcher ensured that the interviews are timely and 
comfortable for the participants, only asked questions related to the research, and 
ensured that the interviews were transcribed correctly. The research was done according 
to the Griffith College Ethics Committee Guiding Principles. 
The participants were mainly from LinkedIn, involving the researcher posting her 
questionnaire link on her LinkedIn page and sending connection requests which included 
a note containing her introduction and link to over 200 people. The researcher also sent 
the link to her contacts all over Ireland. With all these, the researcher was able to get 
219 responses. The researcher was only able to get one response from people that were 
aged 61 and over.  
3.8. INCLUSION AND EXCLUSION CRITERIA 
The questionnaire was opened to everyone living in Ireland only. Anyone who did not 
respond to the link that was sent was automatically excluded from the research. This was 




Also, after reading the introductory letter in the questionnaire, the participants were 
asked if they understood and wanted to carry on with the participation, if they chose the 
NO option, then they were automatically withdrawn from the survey. 
3.9. CONCLUSION.  
For this research, a mixed method of data collection was used. First, a quantitative 
approach using questionnaires for the consumers in Ireland, and a qualitative approach 
of open-ended interviews was used. These methods are in line with the overall research 
philosophy which is Pragmatism. The data collected were analysed and linked to the 
literature review carried out by the researcher in the secondary research and overall 




4. ANALYSIS AND FINDINGS 
4.1. OVERVIEW 
In this chapter, the answers from the surveys will be analysed appropriately to achieve 
the objectives of this research. The objectives encompass the investigation of the 
various challenges affecting the use of wearable devices in the control of the drug 
delivery system in Ireland and to determine the components involved in the connections 
between the wearables and the drug delivery system. The research also examines the 
type of industries that are involved in the development and production of the devices 
and the Irish society’s responsiveness for the new technology based on if they will use 
it. 
4.2. QUANTITATIVE ANALYSIS 
The analysis of the data from the questionnaires helped to define the general 
knowledge of the use of wearable device-controlled drug delivery systems, potential 
market target, and general view about the technology such as what will influence or 
prevent decisions to use the devices. 
4.2.1. GENERAL DATA (Question 1 to 5) 
The total number of responses to the questionnaire was 219, one of the participants 
withdrew from stopped the survey midway so the data collected from the remaining 
218 responses is what was analysed. The number of female participants was 115 and 
the number of male participants was 103. Most of the participants were young people 







Variable  Category  Number of 
responses  
Percent (%) 
Gender Male  103 47.2 
Female 115 52.8 
Age 18-30 121 55.5 
31-40 50 22.9 
41-50 36 16.5 
51-60 10 4.6 
61 and over 1 0.5 
Level of 
Education 
No Formal Education 0 0 
Secondary Education 1 0.5 
Undergraduate 42 19.3 
Post-Graduate 175 80.2 
Yearly income 
(Euros) 
Less than 15,000 107 51.7 
15,001 – 30,000 32 15.5 
30,001– 45,000 31 14 
45,001 – 60,000 29 3.9 
60,001 and above 8 15 
Field of Work Students 41 18.8 
Healthcare 25 11.5 
Pharmaceuticals 28 12.8 
IT 21 9.6 
Construction 14 6.4 
Food and Beverages  4 1.8 
Education 10 4.6 
Finance 16 7.3 
Law 3 1.4 
Others  56 25.7 




4.2.2. INTRODUCTION TO WEARABLE DEVICES (Question 6 to 13) 
This section of the questionnaire was included to determine the rate of the use of 
smartphones and other wearables in Ireland to understand how technological forward 
the Irish society is. 
Question 6, 7 and 8 
This question is to determine the participants’ eagerness to try new technology and to 
determine the experience of using mobile phones and wearables. 214 participants 
(98.2%) made use of their mobile phones every day.  Most of the participants (202) 
said they love getting acquainted with new technology. Also, 52.3% of the respondents 
have experience using wearables with 77 participants still using it and 37 people had 
the device but have abandoned it. 76 people (34.9%) have not used it but are 
interested while are 12.8% of the participant not considering using wearables at all. 





Using my phone is an 
important part of my daily 
activities 
Yes 214 98.2 
No  4 1.8 
I love getting acquainted 
with new technology 
Yes 202 92.7 
No  16 7.3 
Experience of using smart 
bands 
Yes, and I am still using it 
now 
77 35.3 
Yes, but I abandoned it 37 17.0 
No, but I am interested 76 34.9 
No, I never wanted to use 28 12.8 





The analysis above shows that mobile phones and wearable devices are not a new 
phenomenon in Irish society as majority of the population is using or ready to use 
them. They are also interested in getting new technologies which is a good thing for the 
acceptance of wearable device-controlled drug delivery devices.  
Question 9 
This question is a follow-up question that helps determine the type of wearable device 
that is most common/ accepted by the Irish population. The top 4 most wanted/used 
wearable devices in Ireland are Smartwatches (71.6%), Activity Tracker (39.4%), 
Goggle Glass (14.7%), and Smart Clothing (11.0%). 
 
Figure 18: A Graph Showing the Popularity of Different Wearable Devices in Ireland. 
The graph above shows the most popular wearable devices. Companies involved in the 
development and manufacture of wearable device-controlled systems can make use of 
some of these popular wearables for their product. This can, therefore, ease market 




Question 10 and 11 
The data from these questions help to determine when the participant (that own a 
wearable device) started using the device and the frequency of use of the said wearable 
device.  
34 participants have owned a wearable device for over 2 years, 31 participants have 
owned for between 1-2 years, 12 respondents have had it from between 7-12 months 
and 32 people have owned it for between 1 to 6 months. 5 people have owned the 
device for less than a week while the question did not apply to people who have never 
owned the device. 
 
Figure 19: Length of Use of Wearable Device 
52 participants declared that they often wear their wearable device while 28 people said 
they always had it on. 25 people said they only wear the device sometimes and 15 
participants said they rarely wear the device. Like the previous question, this question 
did not apply to people who have never owned the device while 5 people who had the 





Figure 20: Frequency of Use of Wearable Device. 
The data shows that many of those who own these wearable devices make use of 
them, using them frequently no matter the length of ownership of the device. 
Question 12   
This question helps in understanding the views of Irish society about wearable devices. 
Many of the respondents (118) found wearable devices to be very easy to use and 111 

















They are easy to use 118 54.1 
They are very easy to get 44 20.2 
They are useful in improving 
physical health 
112 51.3 
They are very effective 70 32.1 
They are very reliable for data 
recording and data security 
76 34.9 
They are expensive 1 0.5 
I have no idea 39 17.9 
Table 5: Views about Wearable Devices. 
From the data above, it can be concluded that there is a strong affinity for wearable 
devices as it is considered to be easy to use which is very important as it helps increase 
the tendency of people using it. If incorporated in the wearable device-controlled drug 
delivery systems will also allow patients to adhere to the use of their medications. 
Question 13 
The data from this question is to help determine what influences the decision of the 
participants in purchasing wearable devices. Most of the respondents (67.4%) said that 
the internet/social media were the greatest influence. Advertisement and word of 
mouth were the other most common influence with 43.1% and 33.9% respectively.  
Other influences include: 
- Usefulness/ Necessity 





Figure 21: A Graph Showing What Influences the Use of Wearable Devices in Ireland 
The data above shows social input on the behaviour and decision making of the Irish 
consumers in wearable devices. It can be deduced that the use of wearable devices and 
subsequently wearable device-controlled drug delivery systems depend heavily on the 
social perception of the devices. 
4.2.3. INTRODUCTION TO DRUG DELIVERY SYSTEMS (Question 14 to 18) 
This section is to help examine the conventional methods of taking mediation in Ireland 
which is useful in determining the views of consumers on wearable device-controlled 
drug delivery systems. The uses, popularity, and limitation are to be determined. 
Question 14 
The most common type of conventional drug delivery system in Ireland needs to first 
determine. The participants are mostly familiar with tablets (93.1%) and the second 




of injections (Intramuscular, Intravenous, or Subcutaneous). Other conventional drug 
delivery systems are Cream/lotion, Inhalers, Liquid drops, and Patches with the 
percentage familiarity of 56.9%, 56.4%, 52.8%, and 31.2% respectively. 
 
 
Figure 22: Common Conventional Drug Delivery Methods 
 For the above data, oral dosage forms and injectables are the most common drug 
delivery method. From this, we could deduce that the novel drug delivery system using 
these routes may allow for wider acceptance as the consumers are already familiar with 
these methods. 
Question 15 and 16 
A Wearable device-controlled drug delivery system is best used for treating or 
stabilizing prolonged illness. These questions were to ascertain the different types of 









Have you ever been required to 
take medications for more than 2 
weeks? 
Yes 114 52.3 
No 104 47.7 
What was the medication for? Not Applicable 99 45.4 
Fever/ Flu 24 11.0 
Infection 21 9.6 
Asthma 3 1.4 
Hypertension 16 7.3 




Food Poisoning 5 2.3 
Pre and Post Natal 6 2.8 
Others 31 14.2 
Table 6:Common Illness with Prolonged Treatment 
The data above can be used to determine the different treatment areas that the 
wearable device-controlled drug delivery systems can be used. These treatment areas 
can be targeted to help improve the quality of life among the Irish population so that 
they do not require frequent visits to the hospitals. 
Question 17 and 18 
These questions are to help determine the compliance rate of patients in Ireland. First, 
the number of times required to take the medication for the prolonged illness is 
determined and 59.6% of the patients were required to take the medication daily while 
25.2% used the medication several times in a day. 3.2%, 2.8%, and 0.5% of the 
patients were required to use their medication monthly, several times a week, and 





Figure 23: How Often Were You Required to Take Your Medication? 
Secondly, these participants were asked how often they forget to take their 
medications, which is the major question to determine their compliance rate to their 
treatment. 78 participants said they sometimes forget to take their medicine while 83 






Figure 24:How often do you forget to take your medicine? 
The information given above shows that with many of the conventional drug delivery 
systems, the chances of patients missing their medications is high. By using wearable 
device-controlled drug delivery systems, the patients will only be required to make use 
of the device which will automatically control the doses and will prevent them from 
forgetting to take their medication.  
4.2.4. USE OF WEARABLE DEVICE CONTROLLED DRUG SYSTEM (Question 19 to 
25)  
This is the main section of the questionnaire that determines the present state of the 
knowledge of the use of wearable technology as a means of controlling drug delivery 
systems in Ireland. It also provides insights into the views of the Irish population 
regarding the technology. 
Question 19  
This is to determine the popularity of the use of wearable devices in controlling drug 
delivery systems. Only 46 participants were familiar with this type of technology while 






Figure 25: Knowledge about the Use of Wearable Devices in Controlling Drug Delivery Systems 
From this information, it can be concluded that many people in Ireland have no idea or 
are not aware of this technology. This, therefore, shows the present market for the 
technology is very small. 
Question 20  
This is a follow-up question that gives the participants the chance to name the type of 
wearable device-controlled drug delivery systems. Drug pumps especially Insulin Pumps 
were the most common with 7 respondents familiar with the technology. 6 participants 
also knew about smart patches. Other wearable device-controlled drug delivery systems 
known include API infused Contact Lens, Nanoparticles, Subcutaneous Chips, Digital 





Figure 26: Types of Wearable Device-Controlled Drug Delivery System. 
The information above shows that many of the other types of wearable device-
controlled drug delivery systems are not very common. The most known device is the 
insulin pump. 
Question 21 
This question was to help determine the willingness of the participant to buy or use this 
technology. 182 participants would consider using this technology while 36 people said 
they would not consider using the technology. Those who were not interested in trying 
wearable device-controlled drug delivery systems were made up of 16.5% of the people 
aged 18-30, 18% of the people aged 31-40, 13% of the people aged 41-50, and 10% 






Figure 27: Would You Consider Trying This New Technology? 
This shows the acceptance of this type of drug delivery system in Ireland in that 
majority of the population will not refuse to use it if they need to.  
Question 22 
To better understand the views of Irish society on the use of wearable technology as a 
means of controlling drug delivery systems, the factors influencing the choice of the 
device needs to be determined. 73.9% of the participant thought Comfort was very 
important and Effectiveness was considered important by 71.6% of the respondents. 
Also, Ease of use was judged to be essential by 65.6% of the participants and 58.7% of 
the respondents believed Cost to be essential. Size, Look, And Reduced Side Effect was 
perceived by 50%, 36.2%, and 49.5% of the respondents respectively as vital. 
One of the participants added that safety should also be considered as important in the 







Figure 28: Factor Influencing the Choice of Wearable Device-Controlled Drug Delivery Systems. 
It can be deduced that the Size, Look, Comfort, Ease of use, Cost, Effectiveness, 
Reduced Side Effect, and Safety are part of the things that influence the use of 
wearable device-controlled drug delivery systems in Ireland. It shows that before the 
technology can be accepted, information about these listed above is needed to 
influence the decision of the buyer. 
Question 23 and 24 
These questions are follow-up questions on the views of the Irish population on the use 
of the technology. 143 participants believed they would prefer to use the wearable 
device-controlled drug delivery systems instead of the traditional method of drug intake 




Also, 123 participants believe that wearable device-controlled drug delivery systems will 
be more effective than the traditional method of drug intake and 7 respondents do not 
agree that wearable device-controlled drug delivery systems will be more effective while 
88 people simply have no idea of what the efficacy would be. 




Would you prefer this new 
technology to the traditional method 
of drug intake? 
Yes 143 65.6 
No 75 34.4 
Do you think these new drug delivery 
systems will be effective? 
Yes 123 56.4 
No 7 3.2 
I do not know 88 40.4 
Table 7: Preference and Effectiveness of Wearable Device-Controlled Drug Delivery Systems. 
It can be concluded that in Ireland, people are ready for the use of wearable 
technology as a means of controlling drug delivery systems. They would prefer to use 
these systems instead of the regular old method of using medications. 
Question 25 and 26 
To fully understand the views of the people in Ireland on the use of wearable 
technology as a means of controlling drug delivery systems, their fears about the 
technology needs to be captured.  
When asked about their fears, 85 participants indicated to be indifferent about having 
fears, and 73 respondents alleged to have concerns as regards using wearable device-
controlled drug delivery systems while 60 participants were confident in the technology 






Figure 29: Do You Have Fears Concerning Using These New Delivery Systems? 
The participants were then asked to list their fears and concerns about the use of 
wearable technology as a means of controlling drug delivery systems. The cost was a 
major concern, but the following are the list of the other fears/ concerns mentioned by 
the participants: 
1. Effectiveness, efficiency, and accuracy 
2. Unknown or unexpected negative side effects including those caused by radiation 
or adverse reactions to the device. 
3. Infections produced from microorganisms that invade tissue. 
4. Negative environmental effects. 
5. Malfunctioning of the device for example software/hardware/form ware faults 
which can result in drug over/under dose. 
6. Data privacy, storage, and security like malicious tampering, hacking that can 
put the patient's life at risk, and unauthorised access to patients’ medical history. 
7. The potential risks for error at the beginning and lack of validation and approval 
for all the range of patients. 
8. Difficulty to use and Maintenance e.g. Water resistance, Power source, Ease of 




4.3. QUALITATIVE ANALYSIS 
The data from the interviews helped establish any connection between the literature 
review, the result of the questionnaire, and an advanced viewpoint on the effectiveness, 
process, risks, and challenges in the development and manufacture of wearable device-
controlled drug delivery systems. 
Participant 1 had experience in manufacturing API infused contact lens in Johnson & 
Johnson, one of the leading Pharmaceutical companies in Ireland. Participant 2 has 
worked in the medical device industry for over 15 years (in senior management roles) 
and had a start-up company that developed medical devices for medical diagnostics. 
Participant 3 has been the medical device and pharmaceutical industries for over 20 
years in the areas of Validation and Quality Assurance. 
The analysis and observation of the body language, pitch, and tone of the participants 
were inhibited/ not effective has the interview was carried out via Zoom (because of 
COVID 19). 
The interviews with the 3 experts were analysed based on the words and phrases 
common to the response of all the participants. There were 10 recurring themes found 
and they are elaborated below: 
4.3.1. CURRENT TRENDS  
There are different novel Drug Delivery technologies being developed and 
manufactured in the pharmaceutical industries now. All the participants said there are a 
lot of drivers for these new trends in drug delivery, they proceeded to name the ones 
they were familiar with and what drives the current trends in this type of drug delivery 
system. According to Participant 2: 




• Commercial opportunities: Pharmaceutical and medical device industries are 
identifying compelling unmet needs within a therapeutic space and matching that with a 
suitable device that can deliver something.  
• Technology innovation  
I am familiar with wearable device from the implantable type devices, stent coated 
therapeutics. Other are not licensed drug delivery device on the market.  
Over the last 20 years, there has been growth in implantable devices such as drug-
coated stent and I think it will continue to grow as there are still growth and market 
opportunities in endovascular implantable devices. Not only for these devices 
themselves to evolve but also for the therapeutic to evolve and become more 
sophisticated as well. 
The stents usually come in various sizes, design, material, and it is used in different 
locations in the body. The stent coated therapeutics is made up of  
• The therapeutic substance,  
• The delivery apparatus for the correct placing of the stent in the right location of 
the body  
• The stent itself.”  
Also, Participant 3 mentioned that:  
” The current trends among patients is that they want reduced trauma, comfort, and 
reduced stress when it comes to disease treatment and monitoring. I would be familiar 
with the use of wearable devices in controlling drug delivery e.g. Glucose Monitoring 
devices and Insulin Pumps.” 
Participant 1 simply answered with the type of wearable device familiar to him: 
“There are many of these types of devices available now, but I am most familiar with 
API infused contact lenses because I worked in a company that manufactures it. This 





4.3.2. COMPANIES AND PARTNERSHIP  
From the interviews, it could be deduced that there are pharmaceuticals and medical 
device companies in Ireland that are involved in the development and manufacture of 
wearable device-controlled drug delivery systems. Each participant mentioned the 
companies they are familiar with and their products. Participants 2 and 3 mentioned 
Abbott but the products named by the two participants talked about different products 
manufactured by the company. Participant 2 mentioned the company regarding drug-
coated stent: 
“Yes, there are medical device companies that produce stents such as Abbott and 
Stryker. Johnson& Johnson in Limerick also intends to bring a drug-coated product to 
market. Another company in Athlone is producing an implantable device which is an 
osmotic pump for insulin that is at the preapproval stage with the regulatory bodies.”   
While Participant 3 talked about their glucose monitoring system:  
“Abbott manufactures the FreeStyle Libre System which monitors glucose levels in the 
blood. Many multinational companies manufacture this type of device in the world, but 
Abbott's is the market major at the moment. Medtronic in Galway manufacture insulin 
pumps which are used to administer insulin to the body in response to variations in 
glucose levels. Medtronic also manufactures ventilators.” 
Participant 1 talked mainly about companies involved in the manufacture of contact 
lenses in Ireland: 
“The Acuvue contact lenses are manufactured by Vision Care, a branch of Johnson & 
Johnson located in Limerick. Alcon, a UK company in Ireland also produces this device.”   
When asked about the partnerships involved in the manufacture of these technologies, 
all the participants mentioned that it involves the medical device companies who will 
be responsible for creating the wearable device and the pharmaceutical companies 
which will provide the drug substances needed for the treatment of the patients. For 




“In the production of Acuvue lenses, a pharmaceutical company called Amel partnered 
with Johnson & Johnson, Amel will produce the API while Johnson & Johnson will put 
the API into the contact lenses.”  
Participants 2 and 3 further explained that some of the components of the device 
can be outsourced and then the components could be consolidated for final assembly at 
the point of manufacture. It was also suggested that companies should get more than 
one supplier and test the quality. 
Participant 2 added that: 
“These types of devices are called combination devices and the therapeutic substance 
provided by the pharmaceutical company is usually one that has already been tried and 
approved in another form of administration. This technology typically involves taking a 
known drug substance and combining it with a delivery device like the drug-coated 
stent. This a less risky product development strategy. It is also possible that a new drug 
is being developed and the only way of delivering the drug is by combining it with a 
medical device e.g. Inhaler. This will involve the medical company working hand in 
hand with the pharmaceutical companies at the development stage. 
A pharmaceutical company is usually needed for the drug discovery and development 
process involved to get the therapeutic substance approved. While the medical device 
company is needed to design the device that delivers the drug substance. 
Some companies are both medical devices and pharmaceutical companies e.g. GSK and 
Johnson &Johnson that have the means to do everything in-house. 
Sometimes these partnerships can be in the form of a joint venture where they set up a 
separate company allowing them to manage intellectual property issues and share the 
revenue to bring the product to market.” 
Participant 3 provided another insight that: 
“Information technology is very import because a lot of these devices use form-ware 
and software and they must be robustly tested so that when the devices get to the 
market it doesn’t fail. 
Also, there should be a good and strong supply chain of the components. For example, 





Apart from company partnerships, there has to be a strong collaboration between 
different departments in the company like the research and development and product 
development departments so that design and testing work hand in hand at every stage 
of development.” 
4.3.3. PROCESS AND RESOURCES INVOLVED  
According to all the participants, the process for the development and manufacture of 
wearable device-controlled drug delivery systems varies depending on the type of 
wearable device that would be used to control the drug delivery system. For example, 
Participant 2 stated that: 
“I can give you 101 different processes for 101 different products in terms of individual 
steps. It depends on the device itself and the material used in constructing it.” 
He further gave a brief narrative of the basic development steps before the 
manufacturing stage: 
“The first step is the clinical development phase that involves finding molecules and 
drug substances with therapeutic effects. These molecules are then moved through 
basic and applied research discovery. The next step is the Preclinical stage followed 
by the clinical trials /drug safety up until the Market authorization is filed for and 
acquired before the device can be manufacture for commercial purposes.”    
Participant 3 gave a general description of what the manufacturing process would 
involve: 
“…These would include: 
• Manufacture of circuit boards and computer chips in cleanroom environments. 
• Manufacture of device components by extrusion or injection moulding 
• Assembly of devices 
• Testing of devices in line with international standards such as ISO standards. 
• All manufacturing activities must be performed per an accredited Quality 
Management System e.g. ISO13485 for Medical Devices and Eudralex Annex 1 for 
Pharmaceuticals. 




But Participant 1 was able to list the manufacturing steps specific for the manufacture 
of API infused contact lenses: 
“These contact lenses are made from plastic resins. Generally, the drug is added into 
the contact lenses during production. The contact lenses are usually produced in 
different specifications according to the intensity of the eyes. The manufacturing 
process starts with the use of specialized plastic resins. 
• The plastic resins are fist moulded into concave shapes based on the 
specifications. 
• Then the front and back cup of the contact lenses are merged in a process called 
Lens Fabrication. 
• The API is added during the Len fabrication process, it is placed between the 
front and back cups. The lens takes its shape after this process. 
• The next step is sterilization for 48 hrs to prevent bacteria formulation. 
• The content lenses are then cooled and packaged” 
When asked about the general resources needed to ensure the development and 
manufacture of the effective and efficient wearable device-controlled drug delivery 
systems, Participant 2 said: 
“Typically with all of these, you have the drug substances which need to be produced 
and it is usually produced separately and then you have the device itself which usually 
contains several subcomponents that may or may not be produced on-site.” 
While Participant 3 provided a different approach by revealing that: 
“…This would include: 
• Innovative research and development and product design 
• Relevant Funding 
• Strong focus on Ergonomics ensuring the device is compact fits well to the body. 
• Strong focus on ensuring the device is safe and effective.” 
While talking about future processes that will be involved in the manufacture of these 
technologies, Participant 2 projected that: 
“I think it is something that is rapidly changing. The traditional methods involved the 




prevent autoimmune responses. But we were getting to a new age of advanced 
manufacturing where the likes of 3D printing are used as a means of rapid prototyping 
and scale-up manufacturing. These areas are improving and innovating as much as the 
products.” 
4.3.4. EFFECTIVENESS  
When asked about the overall effectiveness of the use of wearable technology as a 
means of controlling drug delivery systems, all the participants agreed to the fact that 
wearable device-controlled drug delivery systems are very effective in increase the 
treatment outcome of diseases and generally improving the quality of life. For example, 
Participants 3 stated that: 
“Yes, I think it is very effective. In my opinion, any wearable drug delivery device that 
reduces the trauma associated with conventional treatments is of great benefit to the 
patient and their families. These types of devices can replace or minimize injections and 
allow people to go about their normal day without having to visit the hospital in some 
occasions. This ultimately takes the pressure off the hospitals and frees up beds for 
other serious cases.   
I would say these technologies in Ireland has improved the lives of patients to date and 
has been quite successful. Especially those with lifelong illnesses such as diabetes and 
kidney failure. As with any Technology as it evolves it will lead to greater success. 
For example, the glucose monitoring device is a leading measure instead of a lagging 
measure because if using the conventional method, the glucose level could be high one 
minute and low the next minute but this device is worn under the elbow and when a 
smartphone is placed there, it scans and shows the glucose levels throughout the day 
and gives real information not just a one-point reading but a trend giving a more 
accurate result that can be acted on quickly. 
Also, insulin pumps are used instead of the conventional method of going to the 
hospital, given a bed, and hooked up on an insulin pump. These insulin pumps can be 
tucked under the shirt and once the monitor detects low insulin levels, it sends signals 
to the pumps which then releases some insulin into the body. It is a close loop system 
that is very effective.”   
Participant 2 also provide another thought based on patient safety and safety, 




“These technologies are good for improving patient safety and compliance. It has also 
reduced the overall burden on the healthcare system. 
Also, the drug-coated stent would be considered effective because there are no 
competitive lower-cost means of providing equivalent benefits. No tablet or injection 
provides equivalent medical benefits at a lower cost. The effectiveness of these drug-
coated stents is backed by data-driven, evidence-based, peer-reviewed papers that 
demonstrate randomised double-blinded studies that show the benefits of these 
technologies when compared with the alternative therapeutics. It has completely 
changed how we practice medicine and improved patient survivability, reduced long 
term side effects, and complications. 
Also, there are opportunities around oncology where you have a therapeutic design for 
a small cohort of cancer patients. Many of these therapeutics are highly potent and 
oncologist usually wants to maximise the dose so that they can safely deliver it to the 
patient in other to maximise the therapeutic benefit which could be made possible by 
the use of drug delivery device rather than the traditional methods.” 
4.3.5. THERAPEUTIC IMPACT 
The use of wearable technology as a means of controlling drug delivery systems is very 
versatile has it can be used in different therapeutic areas. All the participants talked 
about the use of this technology in Diabetes as a therapeutic area with devices such as 
insulin pumps, patches, and injectors. For example, Participant 3 explained that: 
“I think a great impact has been on the treatment of diabetes. Instead of numerous 
finger pricks during the day, the Abbott glucose monitor is attached to the back of the 
elbow and can monitor glucose levels without breaking the skin. The device is so 
lightweight and compact that the patient does not even realize that they are wearing it.  
Diabetes is a disease that is increasing due to lifestyles in the modern world and 
through education and the use of wearable devices, it appears that it can be treated 
effectively and efficiently with little trauma to the patient.” 
Participant 2 expatiated on other areas of impact of the use of wearable technology 
as a means of controlling drug delivery systems. For example, he stated that:  
“Globally, there has been a huge growth in the use of drug-coated stents leading to a 
shift away from open cardiothoracic surgeries to endovascular and intervention type 
surgeries. Drug coated stents are now being offered to patients that about 20 years ago 
will not have to be able to use them because of reasons like risk profile, age, location, 




healthcare systems on the use of stents or because the products were not developed 
enough for such cases. 
Other areas where the use of wearable technology as a means of controlling drug 
delivery systems has been of impact are: 
• There is big growth potential in oncology. In that, the oncology therapeutic are 
usually expensive so the cost of the drug delivery device would be marginal in 
proportion to the price of the actual drug itself.  
• It can be used in chronic ailments where the patients must take their drugs at 
the right time, for example, epilepsy patients. 
• I would say that there has being a lot of success in the manufacture and use of 
wearable devices in terms of diagnostics in Ireland. There would also be a stronger 
future and a lot more success for the use of wearables in diagnostics in Ireland.” 
Another therapeutic area was introduced by Participant 1: 
“The contact lenses are prescribed by medical professionals (opticians) for delivering 
drugs into the eyes. It is used to treat maladies such as cataracts. Different APIs are 
infused into the contact lenses based on the eye ailment. 
During its production, a mechanism for drug release has been provided so when the 
patient wears the lenses, upon contact with the eyes, the API gradually diffuses into the 
eyes and the therapeutic process begins. The API could last for as little as 24 hours 
(single use) up until 72 hours.” 
4.3.6. POPULARITY AND USE IN IRELAND 
The popularity of these devices in Ireland can be analysed based on the number of 
companies producing the technologies and the rate at which people in Ireland use 
these technologies. 
All the participants agree that these technologies are commonly developed and 
manufactured in Ireland as there are some very successful products made in Ireland 
but sold globally. For example, according to Participant 3: 
“Ireland for a small country is high profiled in the field of medical devices, 
pharmaceutical devices, and wearable devices. It may not be up to the top 4 or 5 but it 




they invested for different reasons such as good educational services tailored to suit the 
roles in their companies and the tax benefits they get is good too.” 
When talking about the Glucose Monitoring Device manufactured by Abbot, 
Participant 3 stated that: 
“The device has taken the market by storm. There are good projections for all of 
Europe. One country ordered a full amount and they had to go back and order some 
more” 
Furthermore, Participant 2 provided insights into what is to be expected in the area of 
manufacture of these technologies: 
“There is a huge success on the technologies that are present now, but there is also 
huge potential in terms of the future of these types of technologies with new 
therapeutic, new benefits, innovative designs, and improvement to the technology. 
There are also a lot of new applications of these technologies. The innovative culture is 
expected to continue especially when it comes to medical devices especially from the 
implantable point of view. Although the case may not be the same for pharmaceuticals 
as drug discovery is limited in Ireland.”  
Participant 1 further stated that: 
“The API infused contact lenses are very popular and can be bought from accredited 
stores and online. About 30% of the people using glasses in Ireland use this device. 
The are many brands of these types of devices in Ireland. An example is one made by 
Alcon a UK company in Ireland. Hence, Acuvue lenses although produced over 1 million 
products monthly in Ireland, the product is used more in Asia especially in Japan and 
China because of the high market competition.”    
Participant 3 added that although these technologies are being manufactured in 
Ireland, its use is not as common as seen in other parts of the world:  
“Regarding where we are in using these technologies I believe we are not where we 
should be.” 





“If we talk about drug-coated stents, they are very accessible in Ireland. This has led to 
a huge shift to its use in Ireland.”  
Also, according to Participant 2, the use of wearable devices in diagnosis such as 
blood pressure monitoring is commonly used in Ireland. This device is considered more 
effective than the alternative method because of the ability to record data over time 
and with the recent development in artificial intelligence, these data can be interpreted 
in real-time. 
4.3.7. MANUFACTURING CHALLENGES 
All the participants said there are challenges involved in the manufacture of wearable 
device-controlled drug delivery systems. These challenges like the processes involved 
depend on the type of device being manufactured. Participant 1 mentioned the 
challenges involved in manufacturing the API infused contact lenses as: 
“The presence of heavy regulations and difficulty in getting the API into the wearable 
device (lenses).” 
 While Participant 2 and 3 pronounced that time, money, and resources (especially in 
Research and Development) has the major challenges faced by manufacturers when 
developing and manufacturing wearable device-controlled drug delivery systems.  
Participant 2 mentioned some other challenges and risks involved in manufacturing 
has: 
• “Commercial risks: The market for the device may not exist and the product may 
not be as novel as the manufacturer thought and could be a ‘me too’ technology that 
will end up having a market competition. Market forces determine if the business is 
viable for the said product line.  
• Timing: Delay in entering the market which could be due to reasons such as 
wrong or delayed clinical data or incorrect ‘go to market’ launch plan will have an 
impact on the success of the product.  
• Product Lifecycle: After developing and launching a product, the manufacturer 
cannot determine how long it will take for the product to establish, grow and maintain 
market share before a competing technology comes around and knock out the product 




• Technical risks: The manufacturers try to engine out these risks by knowing and 
understanding their product and manufacturing process. They must identify, minimise, 
and mitigate them.  
• Quality risk: This is the risk of making defective products and the impact that will 
have on the market of the product. 
• Regulatory risks: Regulations are constantly changing during a product’s lifecycle 
and even if the product already gets approval, the rules could still change and affect the 
manufacturing process, the product market, and even marketing license.  
• Unlike America, where it is perfectly lawful to promote and market drugs directly 
to patients that need the product, here in Ireland, it is the Medical professionals and 
HPRA that need to be convinced. A strong case needs to be presented to prove the 
safety, effectiveness, efficacy, and economics of the new technologies when compared 
to the traditional methods.  
• Intellectual property risks: Competitors can use different strategies to keep a 
manufacturer from getting to the market and the competitors could also, even when 
the product enters the market, try can kick their competitors out through aggressive 
Intellectual property strategies.   
Participant 3 also included that some of the challenges include:  
“Bigger companies may bring devices to market quicker which could make devices that 
are still in the development stage obsolete. Also, delays are often incurred during 
validation. However, this can be addressed by taking more time during research and 
development using techniques such as Quality by Design” 
4.3.8. SOLUTIONS TO CHALLENGES 
All the participants were able to provide some insights into how to improve the use of 
wearable technology as a means of controlling drug delivery systems. Some of the 
solutions provided by the participants were directed at making the wearable device-
controlled drug delivery systems more accessible to patients. Participants 2 and 3 
thought that since these technologies are mainly prescribed products, to penetrate the 
market, the manufacturers have to direct their marketing, promotions, and awareness 
to prescribe physicians and healthcare systems and not focus on selling to patients 
Participant 3 anticipated that: 




• By the government subsidizing these to make them widely available and less 
expensive. Also, the companies making these devices in Ireland could make the devices 
affordable through subsidies.  
• Governments and Companies providing grants for R&D and Product development 
which will encourage more companies to invest in this sector. 
• Companies should provide free training on the use of these devices. 
• Companies should advertise the benefits of these devices. 
Participant 2 included: 
• “Regulatory satisfaction: A lot needs to happen for the use of wearable 
technology as a means of controlling drug delivery systems to become mainstream and 
it involved the regulators being comfortable with the technologies. 
• The right approach: Correct physician education and training and ethical 
sponsored researches provide benefits that have a huge impact on the marketability of 
these wearable device-controlled drug delivery systems. Societal believes should also be 
considered when marketing these products among different demographics.    
• Emphasis should be made on the effectiveness and efficacy of these wearable 
device-controlled drug delivery systems especially when compared with the alternatives. 
This tends to improve confidence in the product and justify the overall cost of the 
devices particularly when the alternatives are cheaper. 
• Timing: Companies need to hit the market with the product at the right time 
before competitors get to the market with an exact technology or something better.” 
Participant 1 added that: 
“The use of process validation will help ensure that the product is always made 
according to specifications.” 
4.3.9. USAGE BARRIERS  
The widespread of the use of wearable device-controlled drug delivery systems in 
Ireland has been inhibited because of various hurdles. All participants indicated that the 
high cost of the delivery devices was the most common barrier as listed by all the 
participants. According to Participant 3: 
“This (common barriers) would include:  




• Logistics: As often the patients that require the devices find it hard to reach 
locations where the devices are sold or dispensed therefore, they must rely on the 
existing conventional treatments instead. 
• Availability: People sometimes don’t like to use something new because they 
don’t know if there will be a good steady supply of the product.  
• How advanced the healthcare system is in a country can impact how easy 
patients can get access to these devices. 
• Not ready for change: People are sometimes scared of something new and 
prefer what they had over the past years.”  
Participant 2 added that: 
• “The no advertisement of prescription product regulatory limitations in Ireland is 
also responsible for the lack of awareness of these products among the patients that 
need the product. 
• Safety concerns: Concerns regarding patient safety, adverse reaction, and 
product defect (recalls and withdrawals) can also kill off the market for these 
technologies.”  
Participant 1 claimed that: 
“The use of these technologies is based on the preference of the patient. I prefer to use 
glasses instead of contact lenses. This can be associated with the difficulty of using the 
device. 
According to the market survey carried out by Johnson & Johnson on the use and 
popularity of these API infused contact lenses, the highest user was between age 18 
and 35 and age 65 and above were the lowest so age could be a barrier.”   
4.3.10. IMPROVING ACCEPTANCE  
As regards shifting the views of people in Ireland to accept and embrace the use of this 
technologies, all the participant believe that patients can be swayed by awareness 
about the product (exposing them to the result of clinical research and success of using 
this type of drug delivery system in the form articles or media reports for example). 
All the participant provided insights has to the approaches to be taken by companies, 




“Patients are mostly going to go for the product of there is information on real-life 
experiences from using these devices (customer reviews). The patients also need to be 
educated that the device is more about ensuring that patients benefit from the 
technologies and not about profits for the manufacturers. 
Also making more recyclable devices and helping the environment as well as the 
patients could help improve the acceptance of the devices in Ireland.” 
4.4. CONCLUSION  
From the analysis of the findings provided above, it can be concluded that although 
mobile phones and wearable devices are not a new phenomenon in the Irish society as 
majority of the population are using or ready to use them, the use of these technologies 
by patients to deliver drug substance is still struggling. Oral dosage forms and 
injectables are the most common conventional drug delivery method. But many trends 
are seen that will potentially drive the use of wearable device-controlled systems such 
as the quest for reduced trauma, comfort, and reduced stress. 
One of the reasons for the high use of wearable devices such as Smartwatches, Activity 
Tracker, Goggle Glass, and Smart Clothing, according to the data collected, could be 
associated with the ease of use. It increases the tendency of people using the devices 
which if incorporated in the wearable device-controlled drug delivery systems would 
allow patients to adhere to the use of their medications. It was also deduced that the 
use of wearable devices and subsequently wearable device-controlled drug delivery 
systems depend heavily on the social perception of the devices.  
A Wearable device-controlled drug delivery system is best used for treating or 
stabilizing prolonged or chronic illness. The use of this technology has therefore been 
seen mainly in the monitoring and treatment of diabetes and high blood pressure in 
Ireland and has helped improve the quality of life of Irish society and reduces frequent 
visits to the hospitals. The patients will only be required to make use of the device 





The present market for the wearable device-controlled drug delivery system is very 
small and the only commonly known one is the insulin pump. However, this study was 
able to demonstrate that many people in Ireland would like to use this new technology 
in Ireland. The Irish people would prefer to use these systems instead of the traditional 
method of using medications. But the choice of use of this type of drug delivery system 
in Ireland is based on the Size, Look, Comfort, Ease of use, Cost, Effectiveness, 
Reduced Side Effect and Safety of the devices. Fears and concerns like effectiveness, 
efficiency, and accuracy could also affect the use of wearable technology as a means of 
controlling drug delivery systems in Ireland.  
It was also established that the manufacture of different drug delivery systems such as 
insulin pumps, API infused contact lenses and drug-coated stents by different medical 
devices companies are common in Ireland, and some of these devices are being sold 
globally. The production of these wearable device-controlled drug delivery systems 
involves collaboration between medical device companies and pharmaceutical 
companies. Some components of the device can be outsourced and then the 
components could be consolidated for final assembly at the point of manufacture. Some 
of these devices make use of software and connectivity such as Wi-Fi and Bluetooth 
hence the involvement of information technology departments/companies. 
The process for the development and manufacture of wearable device-controlled drug 
delivery systems varies depending on the type of device. As seen, there are many 
challenges involved in the manufacture and use of wearable device-controlled drug 
delivery systems in Ireland such as heavy regulations and the time, money, and 
resources involved in the Research and Development is high. Also, to penetrate the 
market, manufacturers need to direct their marketing, promotions, and awareness to 
prescribing physicians and healthcare systems. Efforts should be made to make the 





5. CONCLUSIONS AND RECOMMENDATIONS 
5.1. CONCLUSION BY RESEARCH QUESTIONS 
5.1.1. HOW CAN WEARABLE DEVICES BE USED TO CONTROL DRUG DELIVERY 
SYSTEMS?  
The author through literature review and the use of qualitative and quantitative data 
has been able to determine that many different types of wearable devices are being 
used to control drug delivery systems such as stents, wearable injectors, implants, 
smart bracelets, and accessories. Some of these drug delivery systems are worn by the 
patients, attached to the body of the patients, or placed inside the body of the patient 
through surgically means. 
The way each device works varies and is usually based on the drug substance to be 
delivered and the drug delivery system. Mechanisms such as osmosis, diffusion, and 
pumps enable the delivery of the drug substances. One of the benefits of this type of 
drug delivery system is that it is very versatile as one device can be used for different 
drug substances. The process involved in the development and manufacture of 
wearable device-controlled drug delivery systems also varies depending on the type of 
device. 
The quest to satisfy the unmet needs within a therapeutic space and advancement in 
technology innovation are some of the drivers for these new trends in drug delivery. 
The search for reducing trauma and stress and increase comfort when it comes to 
disease treatment and monitoring also contributes to the growth in these technologies. 
It is also estimated that the use of wearable devices in controlling drug delivery systems 
will continue to increase not only for these devices themselves to evolve but also for the 





5.1.2. WHAT TYPE OF INDUSTRIAL COLLABORATIONS ARE INVOLVED IN THE 
CREATION OF THESE DEVICES IN IRELAND AND HOW WILL A SYNERGY 
BETWEEN THE INDUSTRIES BY CERTIFIED? 
The type of partnerships needed for the development and manufacture of wearable 
device-controlled drug delivery systems is determined by the type of process involved. 
Qualitative data collected established that the partnerships required in Ireland are 
usually between the pharmaceuticals and medical devices companies. The medical 
device companies are responsible for designing and creating the wearable device and 
the pharmaceutical companies provide the drug substances needed to be delivered to 
the patients. While the pharmaceutical company is usually needed for the drug 
discovery and development process involved to get the therapeutic substance 
approved. Most of the therapeutic substances used are usually one that has already 
been tried and approved in another form of administration which is a less risky product 
development strategy. Also, a new drug could be developed, and the only way of 
delivering the drug is by combining it with a medical device e.g. Inhaler. The medical 
company and pharmaceutical companies need to work hand in hand, especially at the 
development stage.  
Furthermore, Information technology is very important because a lot of these devices 
use software and it is important that they are robustly tested so that when the devices 
get to the market it does not fail. A strong collaboration between different departments 
in the company like the research and development and product development 
departments are needed to ensure that the design and testing of the product are done 
at every stage of development and manufacture. Finally, some parts of the components 
of the device can be outsourced and the components would be consolidated for final 
assembly at the point of manufacture. This requires rigorous testing of the quality of 
the supplied components and a good supply chain which could be achieved by having 
more than one supplier.  
Many of such partnerships have been seen in Ireland such as the one between Johnson 




the wearable device (contact lenses) and Amel, the pharmaceutical company that 
produces the API. Some multinational companies have both medical device and 
pharmaceutical companies (e.g. GSK and Johnson &Johnson) and have the means to do 
everything in-house. Sometimes these partnerships can be in the form of a joint 
venture where they set up a separate company allowing them to manage intellectual 
property issues and share the revenue to bring the product to market. 
5.1.3. WHAT ARE THE CHALLENGES THAT CAN AFFECT THE USE OF WEARABLE 
DEVICES TO CONTROL DRUG DELIVERY IN IRELAND? 
The challenges affecting the use of wearable devices to control drug delivery in Ireland 
can be analysed from 2 perspectives: 
1. Manufacturers: According to the interviewees, the challenges faced by manufacturers 
in Ireland regarding the development, manufacture, and market penetration are 
numerous and like the processes involved depend on the type of device being 
manufactured. The challenges range from things like the presence of heavy regulations 
to difficulty in getting the drug substance into the wearable device. Time, money, and 
resources (especially in Research and Development) are other major challenges facing 
development and manufacture wearable device-controlled drug delivery systems. Other 
challenges and risks as identified by the qualitative data are Commercial risks, Delay in 
entering the market, Quality risk, Product Lifecycle, Technical risks, and Intellectual 
property risks. 
2. Consumers: The responses from the questionnaire proposed that the use of this type 
of drug delivery system by the people in Ireland has been inhibited because of various 
hurdles such as high cost, Difficulty in usage, Inaccessibility, Lack of steady supply, 
concerns about the patient safety such as adverse reaction to these devices and 
unreadiness to progress from Conventional Healthcare methods. Also, regulatory 
limitations on the advertisement of prescribed medication in Ireland are responsible for 
the lack of awareness of these products among the patients that need the product. Age 




& Johnson on the use and popularity of these API infused contact lenses, the highest 
user was between age 18 and 35 and age 65 and above were the lowest.  
5.1.4. WHO IS THE POTENTIAL TARGET MARKET FOR THIS WEARABLE DEVICE-
CONTROLLED DRUG DELIVERY SYSTEM IN IRELAND?  
According to the quantitative data collected, 85.3% of the participant indicated an 
interest in the use of a wearable device-controlled drug delivery system. When broken 
down according to the age groups, it was seen that the interest in this type of drug 
delivery system cuts across all the age as 83.5% of the people aged 18-30, 82% of the 
people aged 31-40, 87% of the people aged 41-50 and 90% of the people aged 51-60. 
The versatility of wearable device-controlled drug delivery systems has led to its use 
across different therapeutic areas such as diabetes and hypertension. Devices such as 
pumps, patches, and automatic injectors being used in Ireland to deliver insulin to 
diabetic patients and is considered effective and efficient with little trauma to the 
patient. For example, instead of numerous finger pricks involved in the traditional 
method, the Abbott glucose monitor is attached to the back of the elbow and can 
monitor glucose levels without breaking the skin. The device is so lightweight and 
compact that the patient does not even realize that they are wearing it.  Likewise, drug-
coated stents are now being offered to patients that about 20 years ago will not have 
being able to use them because of reasons like risk profile, age, location, or other 
parameters. These technologies are also being targeted to other therapeutic areas such 
as oncology, chronic ailments (epilepsy patients), and real diagnostics and treatment 
combination. 
On another note, many companies are producing these technologies in Ireland for use 
within and outside Ireland. This is due to the high number of medical devices, 
pharmaceutical, and wearable devices multinational companies in Ireland. Many of 
these companies are invested for different reasons such as good educational services 




5.1.5. HOW WILL THIS NEW TECHNOLOGY BE RECEIVED IN THE MARKET IN 
IRELAND? 
This research was able to determine the views of people living in Ireland on wearable 
device-controlled drug delivery systems through quantitative and qualitative data. 
People in the industry because of their advanced knowledge about these technologies 
are confident that wearable device-controlled drug delivery systems are very effective. 
Their views are backed by data-driven, evidence-based, peer-reviewed papers which 
include randomised double-blinded studies that show the benefits of these technologies 
when compared with alternative therapeutics. It is believed that this type of drug 
delivery system has helped improved patient survivability, reduced long term side 
effects, and complications. These devices help to increase the treatment outcome of 
diseases and generally improving the quality of life of the patient and their families. 
They are can be used to replace conventional methods such as intravenous injections 
which ultimately help in improving patient safety and compliance and reduced the 
overall burden on the healthcare system. For example, insulin pumps can be tucked 
under the shirt and once the glucose monitoring device detects low insulin levels, it 
sends a signal to the pumps which then releases some insulin into the body. It is a 
close loop system that is very effective. 
The quantitative data shows that the present market for the technology is very small in 
that majority of people in Ireland have no idea or are not aware of this technology. 
Nevertheless, there is a potential for an increase in the market share as a majority of 
the participant declared that they would be interested and would prefer in using this 
technology instead of the traditional methods. It was also determined that the existing 
and future use of these technologies depends heavily on the social perception of the 
devices. The decision to buy/use the wearable device-controlled drug delivery systems 
is based on mainly on the ease of use, size, look, comfort, ease of use, cost, 
effectiveness, reduced side effect and safety of the devices. Part of the inhibiting 
factors of the use of this type of drug delivery system in Ireland is the fears and 




1. Effectiveness, efficiency, and accuracy 
2. Unknown or unexpected negative side effects including those caused by 
radiation, adverse reaction to the device. 
3. Infections created from microorganisms invading tissue from point of skin 
penetration. 
4. Negative effect on the environment. 
5. Malfunctioning of the device for example software/hardware/form ware faults 
which can result in drug over/under dose. 
6. Data privacy, storage, and security like malicious tampering, hacking that can 
put the patient's life at risk and unauthorised access to a patient’s medical history. 
7. A potential risk for error at the beginning and lack of validation and approval for 
all the range of patients. 
8. Difficulty to use and Maintenance e.g. Water resistance, Power source, Ease of 
replacement in case of damage, and the Internet. 
9. Cost of the Devices 
 
5.2. COMPARING AND CONTRASTING RESULTS FROM PRIMARY AND 
SECONDARY RESEARCH. 
The use of wearable technology as a means of controlling drug delivery systems is taking 
over the pharmaceutical industry at an exponential rate and Ireland is not left behind. 
The different wearable devices used in healthcare to monitor and record patient’s vitals 
are now been used in the delivery of drugs. In some cases, the use of wearables for 
monitoring and recording of patient’s vitals have been incorporated with the capability to 
provide real-time accurate delivery of the drug. The use of wearable devices in controlling 
drug delivery systems has been seen according to this research, has been seen to be as 
beneficial as its use in healthcare monitoring. These benefits like an increase in quality of 
life and increase overall life expectancy are frequently emphasised by different pieces of 
literature (Chiauzzi et al., 2015). 
The challenges facing the manufacture use of wearable device-controlled drug delivery 
devices as seen in the different studies include size, stability, complexity, accuracy, 




sustainable power, connectivity, cost and consistency of use (Goettsche, 2016). This 
research shows that apart from this, the regulation against the advertisement of 
prescribed medication in Ireland prevents direct contact between the manufacturing 
companies and the patients. This, therefore, requires that the attention companies on 
the awareness and education of physicians who can then provide access to the patients. 
Also, data integrity and safety and the access of patients to these technologies were 
uncovered as a major challenge for the use of wearable device-controlled drug delivery 
devices in Ireland. Although connectivity was mentioned as a challenge in the literature 
reviews it has been seen not to be important in all wearable device-controlled drug 
delivery devices such as contact lenses, stents, implantable.  
Finally, although pieces of literature stated age as a barrier for the use of new 
technologies such wearables, in this research the willingness to use of wearable device-
controlled drug delivery devices was not limited by age as the percentage of people who 
were interested in using the technology was above 80% across each age group 18-30, 
31-40, 41-50 and 51-60.  
5.3. CONTRIBUTIONS AND LIMITATIONS OF THE RESEARCH 
The contribution and findings of this study focused on finding out the different types of 
wearable device-controlled drug delivery devices been used, especially in Ireland. While 
most research papers focus on the use, effectiveness, and benefit of the use of 
wearable devices in healthcare for vitals reading and monitoring, this research provided 
an analysis of its use in controlled drug delivery systems. It also provides an 
assessment on the acceptance and views of the use in Ireland. The process and 
challenges involved in the development and manufacture of this type of drug delivery 
system were determined through interviews. The study was also used to determine 
consumer behaviour and intention and general views of these devices through 




The author at the beginning of this research also wanted to measure the effectiveness 
of these novel drug delivery systems but acquiring this type of data required 
conducting/ accessing clinical studies. The author was limited by resources to continue 
in this line. The findings for this research also do not include people above 60 as only 
one participant was gotten for that age group and the number of participants 
interviewed was also limited The reason was that the author chose a convenient 
method for data collection (because of the COVID 19 pandemic) which involved the 
distribution of her questionnaire online limiting access to older people that are less 
tech-savvy. Also, the majority of the participants were young postgraduate degree 
holders therefore, to give a more generalized finding, the study can be imitated on a 
larger and more diverse sample. 
5.4. RECOMMENDATIONS FOR PRACTICE 
This research was able to reveal that quest for reduced trauma, comfort, and reduced 
stress are some of the drivers of the use of wearable device-controlled systems. It was 
also observed that these technologies enable the drug substance to be more effective, 
increasing the treatment outcome. When physicians and patients see a better result 
from these medications, it increases the popularity and use of the medication leading to 
an increase in the overall sales and profit of the drug product, boosting the market 
value of the manufacturer. According to data collected, the use of wearable devices 
depends heavily on the social perception of the devices and other things like the size, 
look, comfort, ease of use, cost, effectiveness, reduced side effect and safety of the 
device. This knowledge can be used by the pharmaceutical industry when developing 
these technologies promoting their acceptance. The fears and concerns of the patients 
should also be taken into consideration. 
The use of wearable technology as a means of controlling drug delivery helps to reduce 
the quantity of the therapeutic substance to be consumed by the patients causing a 
reduction in the money been spent on the drug. It can also be easily used in drug 




are the new methods of improving treatment outcome specific to each patient. Also, by 
using this type of drug delivery system, the patients will only be required to make wear 
or attach the device which will automatically control the doses and will prevent them 
from forgetting to take their medication. 
This research will help in increasing the awareness and knowledge of wearable device-
controlled drug delivery systems as a lack of familiarity with these technologies is also 
responsible for the low usage of the devices. Efforts should be made to make the 
wearable device-controlled drug delivery systems more accessible to patients. The 
government should subsidize these devices to make them widely available and less 
expensive because it is cheaper in the long run if compared to the cost of in-hospital 
visits.  
5.5. RECOMMENDATIONS FOR FUTURE RESEARCH 
Further research needs to be done to determine the best and effective ways to educate 
people on the use of wearables for more than body vitals monitoring and fitness. The 
knowledge of these applications of wearable technology will further promote the 
already increasing market. Also, there can be a comparison study between / 
combination of the use of wearable devices for diagnostics and its use as a means of 
controlling drug delivery systems in Ireland and how these two applications can be used 
to further improve the treatment outcomes. The combination can enhance the use of 
wearable device-controlled drug delivery systems as the existing market of wearable 
devices in diagnostic can be used to drive the market for wearable device-controlled 
drug delivery systems. 
Future research could consider more ways of distributing the questionnaire links and 
the involvement of older volunteers to participate in the filling questionnaire. The 
effectiveness of these devices should also be determined and backed with facts to 




5.6. FINAL CONCLUSION AND REFLECTIONS 
During the course of this research, the author thoroughly went through exciting & 
insightful literature that was helpful in the understanding of the topic “An Analysis of 
the Use of Wearable Technology as a Means of Controlling Drug Delivery Systems and 
the Challenges Facing Its Use in Ireland”.  The review of different well-written literature 
provided an understanding of the different trends in drug delivery around the world. 
The different use of wearable devices and insight into the market for wearable devices 
were acquired. The author was found this process of this research very informative and 
was able to learn more about drug delivery, wearable devices, and numerous 
applications of the use of these technologies. 
The theory and use of this type of drug delivery system have provided amazing benefits 
that will/are revolutionizing healthcare worldwide. The application of these technologies 
is endless, and it is expected to be the next era in pharmaceuticals especially with the 
advancement in technologies such as Artificial Intelligence and IoT. One of the reasons 
for this shift is the steady decline in the pharmaceutical pipeline in the last few years. 
The use of wearable device-controlled drug delivery systems in Ireland is not where it 
should be considering that it houses many multinational companies producing these 
devices. The findings give hope that this will change very soon once the awareness of 
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